Antimicrobial polypeptides

ABSTRACT

The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority or the benefit under 35 U.S.C. 119 ofDanish application nos. PA 2004 00713 and PA 2004 00800 filed May 4,2004 and May 19, 2004, respectively, and U.S. provisional applicationNos. 60/568,583 and 60/574,160 filed May 6, 2004 and May 24, 2004,respectively, the contents of which are fully incorporated herein byreference.

BACKGROUND OF THE INVENTION

In recent years, the variety of antimicrobial agents has increasedsubstantially, along with a parallel increase in resistant pathogenicmicroorganisms. Resistance is now recognized against all clinicallyavailable antimicrobial agents. The response to antimicrobial resistancein the medical community has been to use new or alternative antibioticsnot previously used against the resistant bacteria. This approach hasrequired the continuous development of new antibiotics, either asmodifications of currently existing compounds or as combinations ofcompounds that may inhibit or bypass the bacterial resistancemechanisms.

It is an object of the present invention to provide new polypeptideshaving improved antimicrobial activity and polynucleotides encoding thepolypeptides.

Another object of the invention is to provide new antimicrobialpolypeptides which may have reduced hemolytic activity and/or reducedcytotoxicity. The polypeptides may also exhibit reduced sensitivitytowards cations, such as Ca²⁺, Mg²⁺, and Na⁺.

SUMMARY OF THE INVENTION

In a first aspect the present invention relates to polypeptides havingantimicrobial activity, comprising the amino acid sequence set forth inSEQ ID NO: 2:K-X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-X₁₆-X₁₇;

wherein X₁=N, F, I, W, M, S, A, T, Y, V, H, L, C, K or G; X₂=L, I, F orW; X₃=R, I, F, L, Y, V, A, T, C, H, G, Q or P; X₄=R or C; X₅=I, L, W, M,V or F; X₆=I, L or W; X₇=R, L, T or C; X₈=K, V, F, L, C, Y, I, R, N orW; X₉=G, C, Y, L, F, W or V; X₁₀=I, W, F or R; X₁₁=H, K, C, A, S, I, N,L or Q; X₁₂=I, L, F or V; X₁₃=I, L, F, T or V; X₁₄=K, I, S, L or R;X₁₅=K, R or I; X₁₆=I, L, F or K; X₁₇=G, I, S, L, R, F, T, C or V; and

wherein the amino acid sequence has more than 55% identity and less than100% identity with amino acids 1 to 18 of SEQ ID NO: 1.

In another aspect the present invention relates to polynucleotideshaving a nucleotide sequence which encodes for the polypeptide of theinvention.

In another aspect the present invention relates to a nucleic acidconstruct comprising the nucleotide sequence, which encodes for thepolypeptide of the invention, operably linked to one or more controlsequences that direct the production of the polypeptide in a suitablehost.

In another aspect the present invention relates to a recombinantexpression vector comprising the nucleic acid construct of theinvention.

In another aspect the present invention relates to a recombinant hostcell comprising the nucleic acid construct of the invention.

In another aspect the present invention relates to a method forproducing a polypeptide of the invention, the method comprising: (a)cultivating a recombinant host cell of the invention under conditionsconducive for production of the polypeptide; and (b) recovering thepolypeptide.

Other aspects of the present invention will be apparent from the belowdescription and from the appended claims.

Definitions

Before discussing the present invention in further details, thefollowing terms and conventions will first be defined:

Antimicrobial activity: The term “antimicrobial activity” is definedherein as an activity which is capable of killing or inhibiting growthof microbial cells. In the context of the present invention the term“antimicrobial” is intended to mean that there is a bactericidal and/ora bacteriostatic and/or fungicidal and/or fungistatic effect and/or avirucidal effect, wherein the term “bactericidal” is to be understood ascapable of killing bacterial cells. The term “bacteriostatic” is to beunderstood as capable of inhibiting bacterial growth, i.e., inhibitinggrowing bacterial cells. The term “fungicidal” is to be understood ascapable of killing fungal cells. The term “fungistatic” is to beunderstood as capable of inhibiting fungal growth, i.e., inhibitinggrowing fungal cells. The term “virucidal” is to be understood ascapable of inactivating virus. The term “microbial cells” denotesbacterial or fungal cells (including yeasts).

In the context of the present invention the term “inhibiting growth ofmicrobial cells” is intended to mean that the cells are in thenon-growing state, i.e., that they are not able to propagate.

For purposes of the present invention, antimicrobial activity may bedetermined according to the procedure described by Lehrer et al.,Journal of Immunological Methods, Vol. 137(2): 167-174 (1991).

Polypeptides having antimicrobial activity may be capable of reducingthe number of living cells of Escherichia coli (DSM 1576) to 1/100 after8 hours (preferably after 4 hours, more preferably after 2 hours, mostpreferably after 1 hour, and in particular after 30 minutes) incubationat 20° C. in an aqueous solution of 25% (w/w); preferably in an aqueoussolution of 10% (w/w); more preferably in an aqueous solution of 5%(w/w); even more preferably in an aqueous solution of 1% (w/w); mostpreferably in an aqueous solution of 0.5% (w/w); and in particular in anaqueous solution of 0.1% (w/w) of the polypeptides having antimicrobialactivity.

Polypeptides having antimicrobial activity may also be capable ofinhibiting the outgrowth of Escherichia coli (DSM 1576) for 24 hours at25° C. in a microbial growth substrate, when added in a concentration of1000 ppm; preferably when added in a concentration of 500 ppm; morepreferably when added in a concentration of 250 ppm; even morepreferably when added in a concentration of 100 ppm; most preferablywhen added in a concentration of 50 ppm; and in particular when added ina concentration of 25 ppm.

Polypeptides having antimicrobial activity may be capable of reducingthe number of living cells of Bacillus subtilis (ATCC 6633) to 1/100after 8 hours (preferably after 4 hours, more preferably after 2 hours,most preferably after 1 hour, and in particular after 30 minutes)incubation at 20° C. in an aqueous solution of 25% (w/w); preferably inan aqueous solution of 10% (w/w); more preferably in an aqueous solutionof 5% (w/w); even more preferably in an aqueous solution of 1% (w/w);most preferably in an aqueous solution of 0.5% (w/w); and in particularin an aqueous solution of 0.1% (w/w) of the polypeptides havingantimicrobial activity.

Polypeptides having antimicrobial activity may also be capable ofinhibiting the outgrowth of Bacillus subtilis (ATCC 6633) for 24 hoursat 25° C. in a microbial growth substrate, when added in a concentrationof 1000 ppm; preferably when added in a concentration of 500 ppm; morepreferably when added in a concentration of 250 ppm; even morepreferably when added in a concentration of 100 ppm; most preferablywhen added in a concentration of 50 ppm; and in particular when added ina concentration of 25 ppm.

The polypeptides of the present invention should preferably have atleast 20% of the antimicrobial activity of the polypeptide consisting ofthe amino acid sequence shown as amino acids 1 to 18 of anyone of SEQ IDNO: 5 to SEQ ID NO: 114. In a particular preferred embodiment, thepolypeptides should have at least 40%, such as at least 50%, preferablyat least 60%, such as at least 70%, more preferably at least 80%, suchas at least 90%, most preferably at least 95%, such as about or at least100% of the antimicrobial activity of the polypeptide consisting of theamino acid sequence shown as amino acids 1 to 18 of anyone of SEQ ID NO:5 to SEQ ID NO: 114.

Identity: In the present context, the homology between two amino acidsequences or between two nucleotide sequences is described by theparameter “identity”.

For purposes of the present invention, the degree of identity betweentwo amino acid sequences is determined by using the program FASTAincluded in version 2.0× of the FASTA program package (see W. R. Pearsonand D. J. Lipman, 1988, “Improved Tools for Biological SequenceAnalysis”, PNAS 85: 2444-2448; and W. R. Pearson, 1990 “Rapid andSensitive Sequence Comparison with FASTP and FASTA”, Methods inEnzymology 183: 63-98). The scoring matrix used was BLOSUM50, gappenalty was −12, and gap extension penalty was −2.

The degree of identity between two nucleotide sequences is determinedusing the same algorithm and software package as described above. Thescoring matrix used was the identity matrix, gap penalty was −16, andgap extension penalty was −4.

Fragment: When used herein, a “fragment” of the amino acid sequenceshown as anyone of SEQ ID NO: 5 to SEQ ID NO: 114 is a subsequence ofthe polypeptides wherein one or more amino acids have been deleted fromthe amino and/or carboxyl terminus. Preferably the one or more aminoacids have been deleted from the carboxyl terminus.

Allelic variant: In the present context, the term “allelic variant”denotes any of two or more alternative forms of a gene occupying thesame chromosomal locus. Allelic variation arises naturally throughmutation, and may result in polymorphism within populations. Genemutations can be silent (no change in the encoded polypeptide) or mayencode polypeptides having altered amino acid sequences. An allelicvariant of a polypeptide is a polypeptide encoded by an allelic variantof a gene.

Substantially pure polynucleotide: The term “substantially purepolynucleotide” as used herein refers to a polynucleotide preparation,wherein the polynucleotide has been removed from its natural geneticmilieu, and is thus free of other extraneous or unwanted codingsequences and is in a form suitable for use within geneticallyengineered protein production systems. Thus, a substantially purepolynucleotide contains at the most 10% by weight of otherpolynucleotide material with which it is natively associated (lowerpercentages of other polynucleotide material are preferred, e.g., at themost 8% by weight, at the most 6% by weight, at the most 5% by weight,at the most 4% at the most 3% by weight, at the most 2% by weight, atthe most 1% by weight, and at the most 12% by weight). A substantiallypure polynucleotide may, however, include naturally occurring 5′ and 3′untranslated regions, such as promoters and terminators. It is preferredthat the substantially pure polynucleotide is at least 92% pure, i.e.,that the polynucleotide constitutes at least 92% by weight of the totalpolynucleotide material present in the preparation, and higherpercentages are preferred such as at least 94% pure, at least 95% pure,at least 96% pure, at least 96% pure, at least 97% pure, at least 98%pure, at least 99%, and at the most 99.5% pure. The polynucleotidesdisclosed herein are preferably in a substantially pure form. Inparticular, it is preferred that the polynucleotides disclosed hereinare in “essentially pure form”, i.e., that the polynucleotidepreparation is essentially free of other polynucleotide material withwhich it is natively associated. Herein, the term “substantially purepolynucleotide” is synonymous with the terms “isolated polynucleotide”and “polynucleotide in isolated form”.

Modification(s): In the context of the present invention the term“modification(s)” is intended to mean any chemical modification of thepolypeptide consisting of the amino acid sequence shown as amino acids 1to 18 of anyone of SEQ ID NO: 2 to SEQ ID NO: 114 as well as geneticmanipulation of the DNA encoding the polypeptides. The modification(s)can be replacement(s) of the amino acid side chain(s), substitution(s),deletion(s) and/or insertions(s) in or at the amino acid(s) of interest;or use of unnatural amino acids with similar characteristics in theamino acid sequence. In particular the modification(s) can beamidations, such as amidation of the C-terminus.

cDNA: The term “cDNA” when used in the present context, is intended tocover a DNA molecule which can be prepared by reverse transcription froma mature, spliced, mRNA molecule derived from a eukaryotic cell. cDNAlacks the intron sequences that are usually present in the correspondinggenomic DNA. The initial, primary RNA transcript is a precursor to mRNAand it goes through a series of processing events before appearing asmature spliced mRNA. These events include the removal of intronsequences by a process called splicing. When cDNA is derived from mRNAit therefore lacks intron sequences.

Nucleic acid construct: When used herein, the term “nucleic acidconstruct” means a nucleic acid molecule, either single- ordouble-stranded, which is isolated from a naturally occurring gene orwhich has been modified to contain segments of nucleic acids in a mannerthat would not otherwise exist in nature. The term nucleic acidconstruct is synonymous with the term “expression cassette” when thenucleic acid construct contains the control sequences required forexpression of a coding sequence of the present invention.

Control sequence: The term “control sequences” is defined herein toinclude all components, which are necessary or advantageous for theexpression of a polypeptide of the present invention. Each controlsequence may be native or foreign to the nucleotide sequence encodingthe polypeptide. Such control sequences include, but are not limited to,a leader, polyadenylation sequence, propeptide sequence, promoter,signal peptide sequence, and transcription terminator. At a minimum, thecontrol sequences include a promoter, and transcriptional andtranslational stop signals. The control sequences may be provided withlinkers for the purpose of introducing specific restriction sitesfacilitating ligation of the control sequences with the coding region ofthe nucleotide sequence encoding a polypeptide.

Operably linked: The term “operably linked” is defined herein as aconfiguration in which a control sequence is appropriately placed at aposition relative to the coding sequence of the DNA sequence such thatthe control sequence directs the expression of a polypeptide.

Coding sequence: When used herein the term “coding sequence” is intendedto cover a nucleotide sequence, which directly specifies the amino acidsequence of its protein product. The boundaries of the coding sequenceare generally determined by an open reading frame, which usually beginswith the ATG start codon. The coding sequence typically includes DNA,cDNA, and recombinant nucleotide sequences.

Expression: In the present context, the term “expression” includes anystep involved in the production of the polypeptide including, but notlimited to, transcription, post-transcriptional modification,translation, and post-translational modification. Preferably expressionalso comprises secretion of the polypeptide.

Expression vector: In the present context, the term “expression vector”covers a DNA molecule, linear or circular, that comprises a segmentencoding a polypeptide of the invention, and which is operably linked toadditional segments that provide for its transcription.

Host cell: The term “host cell”, as used herein, includes any cell typewhich is susceptible to transformation with a nucleic acid construct.

The terms “polynucleotide probe”, “hybridization” as well as the variousstringency conditions are defined in the section titled “PolypeptidesHaving Antimicrobial Activity”.

DETAILED DESCRIPTION OF THE INVENTION

Polypeptides Having Antimicrobial Activity

In a first aspect, the present invention relates to polypeptides havingantimicrobial activity and where the polypeptides comprises, preferablyconsists of the amino acid sequence set forth in SEQ ID NO: 2:K-X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-X₁₆-X₁₇; whereinX₁=N, F, I, W, M, S, A, T, Y, V, H, L, C, K or G; preferably X₁=S, T, V,Y, W, I, G, F or L; X₂=L, I, F or W; preferably X₂=W or I; X₃=R, I, F,L, Y, V, A, T, C, H, G, Q or P; preferably X₃=F, I, V or L; X₄=R or C;X₅=I, L, W, M, V or F; preferably X₅=L or I; X₆=I, L, W or Y; preferablyX₆=I; X₇=R, L, T or C; X₈=K, V, F, L, C, Y, I, R, N or W; preferablyX₈=Y, F, W, V or L; X₉=G, C, Y, L, F, W or V; preferably X₉=G or F;X₁₀=I, W, F or R; preferably X₁₀=W or I; X₁₁=H, K, C, A, F, S, I, N, Lor Q; preferably X₁₁=I, S or K; X₁₂=I, L, F or V; preferably X₁₂=L;X₁₃=I, L, F, T or V; preferably X₁₃=L; X₁₄=K, I, S, L or R; preferablyX₁₄=I, R or L; X₁₅=K, R, I or G; X₁₆=Y, I, L, F or K; preferably X₁₆=L;X₁₇=G, I, S, L, R, F, T, C or V; preferably X₁₇=I, F or L; and whereinthe amino acid sequence has more than 55% identity and less than 100%identity with amino acids 1 to 18 of SEQ ID NO: 1. In an embodiment theamino acid sequence has 1, 2, 3, 4, 5, 6, 7 or 8 (preferably 1, 2, 3, 4,5 or 6; more preferably 1, 2, 3, 4 or 5; even more preferably 1, 2, 3 or4; even more preferably 1, 2 or 3; most preferably 1 or 2) amino aciddifferences compared to the amino acid sequence of SEQ ID NO: 1.

In a second aspect, the present invention relates to polypeptides havingantimicrobial activity and where the polypeptides comprises, preferablyconsists of the amino acid sequence set forth in SEQ ID NO: 3:K-R-X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-X₁₆; whereinX₁=L, I, F or W; preferably X₁=W or I; X₂=R, I, F, L, Y, V, A, T, C, H,G, Q or P; preferably X₂=F, I, V or L; X₃=R or C; X₄=I, L, W, M, V or F;preferably X₄=L or I; X₅=I, L or W; preferably X₅=I; X₆=R, L, T or C;X₇=K, V, F, L, C, Y, I, R, N or W; preferably X₇=Y, F, W, V or L; X₈=G,C, Y, L, F, W or V; preferably X₈=G or F; X₉=I, W, F or R; preferablyX₉=W or I; X₁₀=H, K, C, A, S, I, N, L or Q; preferably X₁₀=I, S or K;X₁₁=I, L, F or V; preferably X₁₁=L; X₁₂=I, L, F, T or V; preferablyX₁₂=L; X₁₃=K, I, S, L or R; preferably X₁₃=I, R or L; X₁₄=K, R or I;X₁₅=Y, I, L, F or K; preferably X₁₅=L; X₁₆=G, I, S, L, R, F, T, C or V;preferably X₁₆=I, F or L; and wherein the amino acid sequence has morethan 55% identity and less than 90% identity with amino acids 1 to 18 ofSEQ ID NO: 1. In an embodiment the amino acid sequence has 2, 3, 4, 5,6, 7 or 8 (preferably 2, 3, 4, 5 or 6; more preferably 2, 3, 4 or 5;even more preferably 2, 3 or 4; even more preferably 2 or 3; mostpreferably 2) amino acid differences compared to the amino acid sequenceof SEQ ID NO: 1.

In a third aspect, the present invention relates to polypeptides havingantimicrobial activity and where the polypeptides comprises, preferablyconsists of the amino acid sequence set forth in SEQ ID NO: 4:K-X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-R-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-X₁₆; whereinX₁=N, F, I, W, M, S, A, T, Y, V, H, L, C, K or G; preferably X₁=S, T, V,Y, W, I, G, F or L; X₂=L, I, F or W; preferably X₂=W or I; X₃=R, I, F,L, Y, V, A, T, C, H, G, Q or P; preferably X₃=F, I, V or L; X₄=R or C;X₅=I, L, W, M, V or F; preferably X₅=L or I; X₆=I, L or W; preferablyX₆=I; X₇=R, L, T or C; X₈=K, V, F, L, C, Y, I, R, N or W; preferablyX₈=Y, F, W, V or L; X₉=G, C, Y, L, F, W or V; preferably X₉=G or F;X₁₀=I, W, F or R; preferably X₁₀=W or I; X₁₁=I, L, F or V; preferablyX₁₁=L; X₁₂=I, L, F, T or V; preferably X₁₂=L; X₁₃=K, I, S, L or R;preferably X₁₃=I, R or L; X₁₄=K, R or I; X₁₅=Y, I, L, F or K; preferablyX₁₅=L; X₁₆=G, I, S, L, R, F, T, C or V; preferably X₁₆=I, F or L; andwherein the amino acid sequence has more than 55% identity and less than90% identity with amino acids 1 to 18 of SEQ ID NO: 1. In an embodimentthe amino acid sequence has 2, 3, 4, 5, 6, 7 or 8 (preferably 2, 3, 4, 5or 6; more preferably 2, 3, 4 or 5; even more preferably 2, 3 or 4; evenmore preferably 2 or 3; most preferably 2) amino acid differencescompared to the amino acid sequence of SEQ ID NO: 1.

In an embodiment, the polypeptides of the invention has at least 60%identity with amino acids 1-18 of SEQ ID NO: 1, preferably at least 65%identity, at least 70% identity, at least 75% identity, or at least 80%identity with amino acids 1 to 18 of SEQ ID NO: 1.

In another embodiment, the polypeptides comprises, preferably consistsof amino acids 1 to 18 of anyone of SEQ ID NO: 5 to SEQ ID NO: 114.

The term “anyone of SEQ ID NO: 5 to SEQ ID NO: 114” is intended to meanSEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9,SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ IDNO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28,SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO:33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ IDNO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47,SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO:52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ IDNO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66,SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO:71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ IDNO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85,SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO:90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ IDNO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO:104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO:113, or SEQ ID NO: 114.

In an interesting embodiment, the amino acid sequence differs by at themost five amino acids (e.g., by five amino acids), such as by at themost four amino acids (e.g., by four amino acids), e.g., by at the mostthree amino acids (e.g., by three amino acids), particularly by at themost two amino acids (e.g., by two amino acids), such as by one aminoacid from amino acids 1 to 18 of anyone of SEQ ID NO: 2 to SEQ ID NO:114.

Preferably, the polypeptides of the present invention comprise the aminoacid sequence of anyone of SEQ ID NO: 2 to SEQ ID NO: 114; or a fragmentthereof that has antimicrobial activity.

The term “anyone of SEQ ID NO: 2 to SEQ ID NO: 114” is intended to meanSEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or anyone of SEQ ID NO: 5 toSEQ ID NO: 114.

The amino acids making up the polypeptides of the invention mayindependently be selected from D or L forms.

The polypeptide of the invention may be an artificial variant whichcomprises, preferably consists of, an amino acid sequence that has atthe most three, e.g., at the most two, such as at the most one,substitutions, deletions and/or insertions of amino acids as compared toamino acids 1 to 18 of anyone of SEQ ID NO: 2 to SEQ ID NO: 114. Suchartificial variants may be constructed by standard techniques known inthe art, such as by site-directed/random mutagenesis of the polypeptidecomprising the amino acid sequence shown as amino acids 1 to 18 ofanyone of SEQ ID NO: 2 to SEQ ID NO: 114. In one embodiment of theinvention, amino acid changes are of a minor nature, that isconservative amino acid substitutions that do not significantly affectthe folding and/or activity of the protein; small deletions, typicallyof one to about 5 amino acids; small amino- or carboxyl-terminalextensions, such as an amino-terminal methionine residue; a small linkerpeptide of up to about 10-25 residues; or a small extension thatfacilitates purification by changing net charge or another function,such as a poly-histidine tract, an antigenic epitope or a bindingdomain.

Examples of conservative substitutions are within the group of basicamino acids (arginine, lysine and histidine), acidic amino acids(glutamic acid and aspartic acid), polar amino acids (glutamine andasparagine), hydrophobic amino acids (leucine, isoleucine, valine andmethionine), aromatic amino acids (phenylalanine, tryptophan andtyrosine), and small amino acids (glycine, alanine, serine andthreonine). Amino acid substitutions which do not generally alter thespecific activity are known in the art and are described, for example,by H. Neurath and R. L. Hill, 1979, In, The Proteins, Academic Press,New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile,Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, AlaNaI, Ser/Gly, Tyr/Phe,Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly aswell as these in reverse.

In an interesting embodiment of the invention, the amino acid changesare of such a nature that the physico-chemical properties of thepolypeptides are altered. For example, amino acid changes may beperformed, which improve the thermal stability of the polypeptide, whichalter the substrate specificity, which changes the pH optimum, and thelike.

In another embodiment the amino acid change is an insertion of a smallamino acid (such as glycine, alanine, serine or threonine) after thefirst amino acid (lysine) in the amino acid sequence shown as aminoacids 1 to 18 of anyone of SEQ ID NO: 2 to SEQ ID NO: 114.

N-Terminal Extension

An N-terminal extension of the polypeptides of the invention maysuitably consist of from 1 to 50 amino acids, preferably 2-20 aminoacids, especially 3-15 amino acids. In one embodiment N-terminal peptideextension does not contain an Arg (R). In another embodiment theN-terminal extension comprises a kex2 or kex2-like cleavage site as willbe defined further below. In a preferred embodiment the N-terminalextension is a peptide, comprising at least two Glu (E) and/or Asp (D)amino acid residues, such as an N-terminal extension comprising one ofthe following sequences: EAE, EE, DE and DD.

Kex2 Sites

Kex2 sites (see, e.g., Methods in Enzymology 185, ed. D. Goeddel,Academic Press Inc. (1990), San Diego, Calif., “Gene ExpressionTechnology”) and kex2-like sites are di-basic recognition sites (i.e.,cleavage sites) found between the pro-peptide encoding region and themature region of some proteins.

Insertion of a kex2 site or a kex2-like site have in certain cases beenshown to improve correct endopeptidase processing at the pro-peptidecleavage site resulting in increased protein secretion levels.

In the context of the invention insertion of a kex2 or kex2-like siteresult in the possibility to obtain cleavage at a certain position inthe N-terminal extension resulting in an antimicrobial polypeptide beingextended in comparison to the mature polypeptide shown as amino acids 1to 18 of anyone of SEQ ID NO: 2 to SEQ ID NO: 114.

Fused Polypeptides

The polypeptides of the present invention also include fusedpolypeptides or cleavable fusion polypeptides in which anotherpolypeptide is fused at the N-terminus or the C-terminus of thepolypeptide of the invention or a fragment thereof. A fused polypeptideis produced by fusing a nucleotide sequence (or a portion thereof)encoding another polypeptide to a nucleotide sequence (or a portionthereof) of the present invention. Techniques for producing fusionpolypeptides are known in the art, and include ligating the codingsequences encoding the polypeptides so that they are in frame and thatexpression of the fused polypeptide is under control of the samepromoter(s) and terminator.

Polynucleotides and Nucleotide Sequences

The present invention also relates to polynucleotides having anucleotide sequence which encodes for a polypeptide of the invention. Inparticular, the present invention relates to polynucleotides consistingof a nucleotide sequence which encodes for a polypeptide of theinvention. Due to the degeneracy of the genetic code, the skilled personwill easily recognize that several nucleotide sequences encoding each ofthe polypeptides of the invention may be prepared. It is well known inthe art which nucleotides make up codons encoding the amino acids of thepolypeptides of the invention.

The present invention also relates to polynucleotides which encodefragments of the amino acid sequence shown as anyone of SEQ ID NO: 2 toSEQ ID NO: 114 that have antimicrobial activity. A subsequence of thepolynucleotides is a nucleotide sequence wherein one or more nucleotidesfrom the 5′ and/or 3′ end have been deleted.

The nucleotide sequence may be obtained by standard cloning proceduresused in genetic engineering to relocate the nucleotide sequence from onelocation to a different site where it will be reproduced. The cloningprocedures may involve excision and isolation of a desired fragmentcomprising the nucleotide sequence encoding the polypeptide, insertionof the fragment into a vector molecule, and incorporation of therecombinant vector into a host cell where multiple copies or clones ofthe nucleotide sequence will be replicated. The nucleotide sequence maybe of genomic, cDNA, RNA, semisynthetic, synthetic origin, or anycombinations thereof.

Modification of a nucleotide sequence encoding a polypeptide of thepresent invention may be necessary for the synthesis of a polypeptide,which comprises an amino acid sequence that has at least onesubstitution, deletion and/or insertion as compared to amino acids 1 to18 of anyone of SEQ ID NO: 2 to SEQ ID NO: 114. These artificialvariants may differ in some engineered way from the polypeptide isolatedfrom its native source, e.g., variants that differ in specific activity,thermostability, pH optimum, or the like.

It will be apparent to those skilled in the art that such modificationscan be made outside the regions critical to the function of the moleculeand still result in an active polypeptide. Amino acid residues essentialto the activity of the polypeptide encoded by the nucleotide sequence ofthe invention, and therefore preferably not subject to modification,such as substitution, may be identified according to procedures known inthe art, such as site-directed mutagenesis or alanine-scanningmutagenesis (see, e.g., Cunningham and Wells, 1989, Science 244:1081-1085). In the latter technique, mutations are introduced at everypositively charged residue in the molecule, and the resultant mutantmolecules are tested for antimicrobial activity to identify amino acidresidues that are critical to the activity of the molecule. Sites ofsubstrate-enzyme interaction can also be determined by analysis of thethree-dimensional structure as determined by such techniques as nuclearmagnetic resonance analysis, crystallography or photoaffinity labelling(see, e.g., de Vos et al., 1992, Science 255: 306-312; Smith et al.,1992, Journal of Molecular Biology 224: 899-904; Wlodaver et al., 1992,FEBS Letters 309: 59-64).

Moreover, a nucleotide sequence encoding a polypeptide of the presentinvention may be modified by introduction of nucleotide substitutionswhich do not give rise to another amino acid sequence of the polypeptideencoded by the nucleotide sequence, but which correspond to the codonusage of the host organism intended for production of the enzyme.

The introduction of a mutation into the nucleotide sequence to exchangeone nucleotide for another nucleotide may be accomplished bysite-directed mutagenesis using any of the methods known in the art.Particularly useful is the procedure, which utilizes a supercoiled,double stranded DNA vector with an insert of interest and two syntheticprimers containing the desired mutation. The oligonucleotide primers,each complementary to opposite strands of the vector, extend duringtemperature cycling by means of Pfu DNA polymerase. On incorporation ofthe primers, a mutated plasmid containing staggered nicks is generated.Following temperature cycling, the product is treated with DpnI which isspecific for methylated and hemimethylated DNA to digest the parentalDNA template and to select for mutation-containing synthesized DNA.Other procedures known in the art may also be used. For a generaldescription of nucleotide substitution, see, e.g., Ford et al., 1991,Protein Expression and Purification 2: 95-107.

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprisinga nucleotide sequence of the present invention operably linked to one ormore control sequences that direct the expression of the coding sequencein a suitable host cell under conditions compatible with the controlsequences.

A nucleotide sequence encoding a polypeptide of the present inventionmay be manipulated in a variety of ways to provide for expression of thepolypeptide. Manipulation of the nucleotide sequence prior to itsinsertion into a vector may be desirable or necessary depending on theexpression vector. The techniques for modifying nucleotide sequencesutilizing recombinant DNA methods are well known in the art.

The control sequence may be an appropriate promoter sequence, anucleotide sequence which is recognized by a host cell for expression ofthe nucleotide sequence. The promoter sequence contains transcriptionalcontrol sequences, which mediate the expression of the polypeptide. Thepromoter may be any nucleotide sequence which shows transcriptionalactivity in the host cell of choice including mutant, truncated, andhybrid promoters, and may be obtained from genes encoding extracellularor intracellular polypeptides either homologous or heterologous to thehost cell.

Examples of suitable promoters for directing the transcription of thenucleic acid constructs of the present invention, especially in abacterial host cell, are the promoters obtained from the E. coli lacoperon, Streptomyces coelicolor agarase gene (dagA), Bacillus subtilislevansucrase gene (sacB), Bacillus licheniformis alpha-amylase gene(amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM),Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacilluslicheniformis penicillinase gene (penP), Bacillus subtilis xylA and xylBgenes, and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978,Proceedings of the National Academy of Sciences USA 75: 3727-3731), aswell as the tac promoter (DeBoer et al., 1983, Proceedings of theNational Academy of Sciences USA 80: 21-25). Further promoters aredescribed in “Useful proteins from recombinant bacteria” in ScientificAmerican, 1980, 242: 74-94; and in Sambrook et al., 1989, supra.

Examples of suitable promoters for directing the transcription of thenucleic acid constructs of the present invention in a filamentous fungalhost cell are promoters obtained from the genes for Aspergillus oryzaeTAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus nigerneutral alpha-amylase, Aspergillus niger acid stable alpha-amylase,Aspergillus niger or Aspergillus awamori glucoamylase (glaA), Rhizomucormiehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzaetriose phosphate isomerase, Aspergillus nidulans acetamidase, andFusarium oxysporum trypsin-like protease (WO 96/00787), as well as theNA2-tpi promoter (a hybrid of the promoters from the genes forAspergillus niger neutral alpha-amylase and Aspergillus oryzae triosephosphate isomerase), and mutant, truncated, and hybrid promotersthereof.

In a yeast host, useful promoters are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiaegalactokinase (GAL1), Saccharomyces cerevisiae alcoholdehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP), andSaccharomyces cerevisiae 3-phosphoglycerate kinase. Other usefulpromoters for yeast host cells are described by Romanos et al., 1992,Yeast 8: 423-488.

The control sequence may also be a suitable transcription terminatorsequence, a sequence recognized by a host cell to terminatetranscription. The terminator sequence is operably linked to the 3′terminus of the nucleotide sequence encoding the polypeptide. Anyterminator which is functional in the host cell of choice may be used inthe present invention.

Preferred terminators for filamentous fungal host cells are obtainedfrom the genes for Aspergillus oryzae TAKA amylase, Aspergillus nigerglucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillusniger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae enolase, Saccharomyces cerevisiaecytochrome C (CYC1), and Saccharomyces cerevisiaeglyceraldehyde-3-phosphate dehydrogenase. Other useful terminators foryeast host cells are described by Romanos et al., 1992, supra.

The control sequence may also be a suitable leader sequence, anontranslated region of an mRNA which is important for translation bythe host cell. The leader sequence is operably linked to the 5′ terminusof the nucleotide sequence encoding the polypeptide. Any leader sequencethat is functional in the host cell of choice may be used in the presentinvention.

Preferred leaders for filamentous fungal host cells are obtained fromthe genes for Aspergillus oryzae TAKA amylase and Aspergillus nidulanstriose phosphate isomerase.

Suitable leaders for yeast host cells are obtained from the genes forSaccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-factor, andSaccharomyces cerevisiae alcoholdehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

The control sequence may also be a polyadenylation sequence, a sequenceoperably linked to the 3′ terminus of the nucleotide sequence and which,when transcribed, is recognized by the host cell as a signal to addpolyadenosine residues to transcribed mRNA. Any polyadenylation sequencewhich is functional in the host cell of choice may be used in thepresent invention.

Preferred polyadenylation sequences for filamentous fungal host cellsare obtained from the genes for Aspergillus oryzae TAKA amylase,Aspergillus niger glucoamylase, Aspergillus nidulans anthranilatesynthase, Fusarium oxysporum trypsin-like protease, and Aspergillusniger alpha-glucosidase.

Useful polyadenylation sequences for yeast host cells are described byGuo and Sherman, 1995, Molecular Cellular Biology 15: 5983-5990.

The control sequence may also be a signal peptide coding region thatcodes for an amino acid sequence linked to the amino terminus of apolypeptide and directs the encoded polypeptide into the cell'ssecretory pathway. The 5′ end of the coding sequence of the nucleotidesequence may inherently contain a signal peptide coding region naturallylinked in translation reading frame with the segment of the codingregion which encodes the secreted polypeptide. Alternatively, the 5′ endof the coding sequence may contain a signal peptide coding region whichis foreign to the coding sequence. The foreign signal peptide codingregion may be required where the coding sequence does not naturallycontain a signal peptide coding region. Alternatively, the foreignsignal peptide coding region may simply replace the natural signalpeptide coding region in order to enhance secretion of the polypeptide.However, any signal peptide coding region which directs the expressedpolypeptide into the secretory pathway of a host cell of choice may beused in the present invention.

Effective signal peptide coding regions for bacterial host cells are thesignal peptide coding regions obtained from the genes for Bacillus NCIB11837 maltogenic amylase, Bacillus stearothermophilus alpha-amylase,Bacillus licheniformis subtilisin, Bacillus licheniformisbeta-lactamase, Bacillus stearothermophilus neutral proteases (nprT,nprS, nprM), and Bacillus subtilis prsA. Further signal peptides aredescribed by Simonen and Palva, 1993, Microbiological Reviews 57:109-137.

Effective signal peptide coding regions for filamentous fungal hostcells are the signal peptide coding regions obtained from the genes forAspergillus oryzae TAKA amylase, Aspergillus niger neutral amylase,Aspergillus niger glucoamylase, Rhizomucor miehei aspartic proteinase,Humicola insolens cellulase, and Humicola lanuginosa lipase.

Useful signal peptides for yeast host cells are obtained from the genesfor Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiaeinvertase. Other useful signal peptide coding regions are described byRomanos et al., 1992, supra.

The control sequence may also be a propeptide coding region that codesfor an amino acid sequence positioned at the amino terminus of apolypeptide. The resultant polypeptide is known as a proenzyme orpropolypeptide (or a zymogen in some cases). A propolypeptide isgenerally inactive and can be converted to a mature active polypeptideby catalytic or autocatalytic cleavage of the propeptide from thepropolypeptide. The propeptide coding region may be obtained from thegenes for Bacillus subtilis alkaline protease (aprE), Bacillus subtilisneutral protease (nprT), Saccharomyces cerevisiae alpha-factor,Rhizomucor miehei aspartic proteinase, and Myceliophthora thermophilalaccase (WO 95/33836).

Where both signal peptide and propeptide regions are present at theamino terminus of a polypeptide, the propeptide region is positionednext to the amino terminus of a polypeptide and the signal peptideregion is positioned next to the amino terminus of the propeptideregion.

It may also be desirable to add regulatory sequences which allow theregulation of the expression of the polypeptide relative to the growthof the host cell. Examples of regulatory systems are those which causethe expression of the gene to be turned on or off in response to achemical or physical stimulus, including the presence of a regulatorycompound. Regulatory systems in prokaryotic systems include the lac,tac, and trp operator systems. In yeast, the ADH2 system or GAL1 systemmay be used. In filamentous fungi, the TAKA alpha-amylase promoter,Aspergillus niger glucoamylase promoter, and Aspergillus oryzaeglucoamylase promoter may be used as regulatory sequences. Otherexamples of regulatory sequences are those which allow for geneamplification. In eukaryotic systems, these include the dihydrofolatereductase gene which is amplified in the presence of methotrexate, andthe metallothionein genes which are amplified with heavy metals. Inthese cases, the nucleotide sequence encoding the polypeptide would beoperably linked with the regulatory sequence.

Expression Vectors

The present invention also relates to recombinant expression vectorscomprising the nucleic acid construct of the invention. The variousnucleotide and control sequences described above may be joined togetherto produce a recombinant expression vector which may include one or moreconvenient restriction sites to allow for insertion or substitution ofthe nucleotide sequence encoding the polypeptide at such sites.Alternatively, the nucleotide sequence of the present invention may beexpressed by inserting the nucleotide sequence or a nucleic acidconstruct comprising the sequence into an appropriate vector forexpression. In creating the expression vector, the coding sequence islocated in the vector so that the coding sequence is operably linkedwith the appropriate control sequences for expression.

The recombinant expression vector may be any vector (e.g., a plasmid orvirus) which can be conveniently subjected to recombinant DNA proceduresand can bring about the expression of the nucleotide sequence. Thechoice of the vector will typically depend on the compatibility of thevector with the host cell into which the vector is to be introduced. Thevectors may be linear or closed circular plasmids.

The vector may be an autonomously replicating vector, i.e., a vectorwhich exists as an extrachromosomal entity, the replication of which isindependent of chromosomal replication, e.g., a plasmid, anextrachromosomal element, a minichromosome, or an artificial chromosome.

The vector may contain any means for assuring self-replication.Alternatively, the vector may be one which, when introduced into thehost cell, is integrated into the genome and replicated together withthe chromosome(s) into which it has been integrated. Furthermore, asingle vector or plasmid or two or more vectors or plasmids whichtogether contain the total DNA to be introduced into the genome of thehost cell, or a transposon may be used.

The vectors of the present invention preferably contain one or moreselectable markers which permit easy selection of transformed cells. Aselectable marker is a gene the product of which provides for biocide orviral resistance, resistance to heavy metals, prototrophy to auxotrophs,and the like.

Examples of bacterial selectable markers are the daI genes from Bacillussubtilis or Bacillus licheniformis, or markers which confer antibioticresistance such as ampicillin, kanamycin, chloramphenicol ortetracycline resistance. Suitable markers for yeast host cells are ADE2,HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in afilamentous fungal host cell include, but are not limited to, amdS(acetamidase), argB (ornithine carbamoyltransferase), bar(phosphinothricin acetyltransferase), hygB (hygromycinphosphotransferase), niaD (nitrate reductase), pyrG(orotidine-5′-phosphate decarboxylase), sC (sulfate adenyltransferase),trpC (anthranilate synthase), as well as equivalents thereof.

Preferred for use in an Aspergillus cell are the amdS and pyrG genes ofAspergillus nidulans or Aspergillus oryzae and the bar gene ofStreptomyces hygroscopicus.

The vectors of the present invention preferably contain an element(s)that permits stable integration of the vector into the host cell'sgenome or autonomous replication of the vector in the cell independentof the genome.

For integration into the host cell genome, the vector may rely on thenucleotide sequence encoding the polypeptide or any other element of thevector for stable integration of the vector into the genome byhomologous or nonhomologous recombination. Alternatively, the vector maycontain additional nucleotide sequences for directing integration byhomologous recombination into the genome of the host cell. Theadditional nucleotide sequences enable the vector to be integrated intothe host cell genome at a precise location(s) in the chromosome(s). Toincrease the likelihood of integration at a precise location, theintegrational elements should preferably contain a sufficient number ofnucleotides, such as 100 to 1,500 base pairs, preferably 400 to 1,500base pairs, and most preferably 800 to 1,500 base pairs, which arehighly homologous with the corresponding target sequence to enhance theprobability of homologous recombination. The integrational elements maybe any sequence that is homologous with the target sequence in thegenome of the host cell. Furthermore, the integrational elements may benon-encoding or encoding nucleotide sequences. On the other hand, thevector may be integrated into the genome of the host cell bynon-homologous recombination.

For autonomous replication, the vector may further comprise an origin ofreplication enabling the vector to replicate autonomously in the hostcell in question. Examples of bacterial origins of replication are theorigins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184permitting replication in E. coli, and pUB110, pE194, pTA1060, and pAMβ1permitting replication in Bacillus. Examples of origins of replicationfor use in a yeast host cell are the 2 micron origin of replication,ARS1, ARS4, the combination of ARS1 and CEN3, and the combination ofARS4 and CEN6. The origin of replication may be one having a mutationwhich makes its functioning temperature-sensitive in the host cell (see,e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA75: 1433).

More than one copy of a nucleotide sequence of the present invention maybe inserted into the host cell to increase production of the geneproduct. An increase in the copy number of the nucleotide sequence canbe obtained by integrating at least one additional copy of the sequenceinto the host cell genome or by including an amplifiable selectablemarker gene with the nucleotide sequence where cells containingamplified copies of the selectable marker gene, and thereby additionalcopies of the nucleotide sequence, can be selected for by cultivatingthe cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to constructthe recombinant expression vectors of the present invention are wellknown to one skilled in the art (see, e.g., Sambrook et al., 1989,supra).

Host Cells

The present invention also relates to recombinant a host cell comprisingthe nucleic acid construct of the invention, which are advantageouslyused in the recombinant production of the polypeptides. A vectorcomprising a nucleotide sequence of the present invention is introducedinto a host cell so that the vector is maintained as a chromosomalintegrant or as a self-replicating extra-chromosomal vector as describedearlier.

The host cell may be a unicellular microorganism, e.g., a prokaryote, ora non-unicellular microorganism, e.g., a eukaryote.

Useful unicellular cells are bacterial cells such as gram positivebacteria including, but not limited to, a Bacillus cell, e.g., Bacillusalkalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacilluscirculans, Bacillus clausii, Bacillus coagulans, Bacillus lautus,Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillusstearothermophilus, Bacillus subtilis, and Bacillus thuringiensis; or aStreptomyces cell, e.g., Streptomyces lividans or Streptomyces murinus,or gram negative bacteria such as E. coli and Pseudomonas sp. In apreferred embodiment, the bacterial host cell is a Bacillus lentus,Bacillus licheniformis, Bacillus stearothermophilus, or Bacillussubtilis cell. In another preferred embodiment, the Bacillus cell is analkalophilic Bacillus.

The introduction of a vector into a bacterial host cell may, forinstance, be effected by protoplast transformation (see, e.g., Chang andCohen, 1979, Molecular General Genetics 168: 111-115), using competentcells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81:823-829, or Dubnau and Davidoff-Abelson, 1971, Journal of MolecularBiology 56: 209-221), electroporation (see, e.g., Shigekawa and Dower,1988, Biotechniques 6: 742-751), or conjugation (see, e.g., Koehler andThorne, 1987, Journal of Bacteriology 169: 5771-5278).

The host cell may be a eukaryote, such as a mammalian, insect, plant, orfungal cell.

In a preferred embodiment, the host cell is a fungal cell. “Fungi” asused herein includes the phyla Ascomycota, Basidiomycota,Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In,Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CABInternational, University Press, Cambridge, UK) as well as the Oomycota(as cited in Hawksworth et al., 1995, supra, page 171) and allmitosporic fungi (Hawksworth et al., 1995, supra).

In a more preferred embodiment, the fungal host cell is a yeast cell.“Yeast” as used herein includes ascosporogenous yeast (Endomycetales),basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti(Blastomycetes). Since the classification of yeast may change in thefuture, for the purposes of this invention, yeast shall be defined asdescribed in Biology and Activities of Yeast (Skinner, F. A., Passmore,S. M., and Davenport, R. R., eds, Soc. App. Bacteriol. Symposium SeriesNo. 9, 1980).

In an even more preferred embodiment, the yeast host cell is a Candida,Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, orYarrowia cell.

In a most preferred embodiment, the yeast host cell is a Saccharomycescarlsbergensis, Saccharomyces cerevisiae, Saccharomyces diastaticus,Saccharomyces douglasii, Saccharomyces kluyveri, Saccharomyces norbensisor Saccharomyces oviformis cell. In another most preferred embodiment,the yeast host cell is a Kluyveromyces lactis cell. In another mostpreferred embodiment, the yeast host cell is a Yarrowia lipolytica cell.

In another more preferred embodiment, the fungal host cell is afilamentous fungal cell. “Filamentous fungi” include all filamentousforms of the subdivision Eumycota and Oomycota (as defined by Hawksworthet al., 1995, supra). The filamentous fungi are characterized by amycelial wall composed of chitin, cellulose, glucan, chitosan, mannan,and other complex polysaccharides. Vegetative growth is by hyphalelongation and carbon catabolism is obligately aerobic. In contrast,vegetative growth by yeasts such as Saccharomyces cerevisiae is bybudding of a unicellular thallus and carbon catabolism may befermentative.

In an even more preferred embodiment, the filamentous fungal host cellis a cell of a species of, but not limited to, Acremonium, Aspergillus,Fusarium, Humicola, Mucor, Myceliophthora, Neurospora, Penicillium,Thielavia, Tolypocladium, or Trichoderma.

In a most preferred embodiment, the filamentous fungal host cell is anAspergillus awamori, Aspergillus foetidus, Aspergillus japonicus,Aspergillus nidulans, Aspergillus niger or Aspergillus oryzae cell. Inanother most preferred embodiment, the filamentous fungal host cell is aFusarium bactridioides, Fusarium cerealis, Fusarium crookwellense,Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusariumheterosporum, Fusarium negundi, Fusarium oxysporum, Fusariumreticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum,Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum,Fusarium trichothecioides, or Fusarium venenatum cell. In an even mostpreferred embodiment, the filamentous fungal parent cell is a Fusariumvenenatum (Nirenberg sp. nov.) cell. In another most preferredembodiment, the filamentous fungal host cell is a Humicola insolens,Humicola lanuginosa, Mucor miehei, Myceliophthora thermophila,Neurospora crassa, Penicillium purpurogenum, Thielavia terrestris,Trichoderma harzianum, Trichoderma koningii, Trichodermalongibrachiatum, Trichoderma reesei, or Trichoderma viride cell.

Fungal cells may be transformed by a process involving protoplastformation, transformation of the protoplasts, and regeneration of thecell wall in a manner known per se. Suitable procedures fortransformation of Aspergillus host cells are described in EP 238 023 andYelton et al., 1984, Proceedings of the National Academy of Sciences USA81: 1470-1474. Suitable methods for transforming Fusarium species aredescribed by Malardier et al., 1989, Gene 78: 147-156 and WO 96/00787.Yeast may be transformed using the procedures described by Becker andGuarente, In Abelson, J. N. and Simon, M. I., editors, Guide to YeastGenetics and Molecular Biology, Methods in Enzymology, 194: 182-187,Academic Press, Inc., New York; Ito et al., 1983, Journal ofBacteriology 153: 163; and Hinnen et al., 1978, Proceedings of theNational Academy of Sciences USA 75: 1920.

Methods of Production

The present invention also relates to methods for producing apolypeptide of the present invention comprising (a) cultivating a hostcell under conditions conducive for production of the polypeptide; and(b) recovering the polypeptide.

In the production methods of the present invention, the cells arecultivated in a nutrient medium suitable for production of thepolypeptide using methods known in the art. For example, the cell may becultivated by shake flask cultivation, small-scale or large-scalefermentation (including continuous, batch, fed-batch, or solid statefermentations) in laboratory or industrial fermentors performed in asuitable medium and under conditions allowing the polypeptide to beexpressed and/or isolated. The cultivation takes place in a suitablenutrient medium comprising carbon and nitrogen sources and inorganicsalts, using procedures known in the art. Suitable media are availablefrom commercial suppliers or may be prepared according to publishedcompositions (e.g., in catalogues of the American Type CultureCollection). If the polypeptide is secreted into the nutrient medium,the polypeptide can be recovered directly from the medium. If thepolypeptide is not secreted, it can be recovered from cell lysates.

The polypeptides may be detected using methods known in the art that arespecific for the polypeptides. These detection methods may include useof specific antibodies, formation of an enzyme product, or disappearanceof an enzyme substrate. For example, an enzyme assay may be used todetermine the activity of the polypeptide as described herein.

The resulting polypeptide may be recovered by methods known in the art.For example, the polypeptide may be recovered from the nutrient mediumby conventional procedures including, but not limited to,centrifugation, filtration, extraction, spray-drying, evaporation, orprecipitation.

The polypeptides of the present invention may be purified by a varietyof procedures known in the art including, but not limited to,chromatography (e.g., ion exchange, affinity, hydrophobic,chromatofocusing, and size exclusion), electrophoretic procedures (e.g.,preparative isoelectric focusing), differential solubility (e.g.,ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g.,Protein Purification, J.-C. Janson and Lars Ryden, editors, VCHPublishers, New York, 1989).

Plants

The present invention also relates to a transgenic plant, plant part, orplant cell which has been transformed with a nucleotide sequenceencoding a polypeptide having antimicrobial activity of the presentinvention so as to express and produce the polypeptide in recoverablequantities. The polypeptide may be recovered from the plant or plantpart. Alternatively, the plant or plant part containing the recombinantpolypeptide may be used as such for improving the quality of a food orfeed, e.g., improving nutritional value, palatability, and rheologicalproperties, or to destroy an antinutritive factor. The recoveredpolypeptide, plant or plant part may also be used to improve or alterdigestive flora in animals and livestock.

The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous(a monocot). Examples of monocot plants are grasses, such as meadowgrass (blue grass, Poa), forage grass such as Festuca, Lolium, temperategrass, such as Agrostis, and cereals, e.g., wheat, oats, rye, barley,rice, sorghum, and maize (corn).

Examples of dicot plants are tobacco, potato, sugar beet, legumes, suchas lupins, pea, bean and soybean, and cruciferous plants (familyBrassicaceae), such as cauliflower, rape seed, and the closely relatedmodel organism Arabidopsis thaliana.

Examples of plant parts are stem, callus, leaves, root, fruits, seeds,and tubers. Also specific plant tissues, such as chloroplast, apoplast,mitochondria, vacuole, peroxisomes, and cytoplasm are considered to be aplant part. Furthermore, any plant cell, whatever the tissue origin, isconsidered to be a plant part.

Also included within the scope of the present invention are the progenyof such plants, plant parts and plant cells.

The transgenic plant or plant cell expressing a polypeptide of thepresent invention may be constructed in accordance with methods known inthe art. Briefly, the plant or plant cell is constructed byincorporating one or more expression constructs encoding a polypeptideof the present invention into the plant host genome and propagating theresulting modified plant or plant cell into a transgenic plant or plantcell.

Conveniently, the expression construct is a nucleic acid construct whichcomprises a nucleotide sequence encoding a polypeptide of the presentinvention operably linked with appropriate regulatory sequences requiredfor expression of the nucleotide sequence in the plant or plant part ofchoice. Furthermore, the expression construct may comprise a selectablemarker useful for identifying host cells into which the expressionconstruct has been integrated and DNA sequences necessary forintroduction of the construct into the plant in question (the latterdepends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminatorsequences and optionally signal or transit sequences, is determined, forexample, on the basis of when, where, and how the polypeptide is desiredto be expressed. For instance, the expression of the gene encoding apolypeptide of the present invention may be constitutive or inducible,or may be developmental, stage or tissue specific, and the gene productmay be targeted to a specific tissue or plant part such as seeds orleaves. Regulatory sequences are, for example, described by Tague etal., 1988, Plant Physiology 86: 506.

For constitutive expression, the ³⁵S-CaMV promoter may be used (Francket al., 1980, Cell 21: 285-294). Organ-specific promoters may be, forexample, a promoter from storage sink tissues such as seeds, potatotubers, and fruits (Edwards & Coruzzi, 1990, Ann. Rev. Genet. 24:275-303), or from metabolic sink tissues such as meristems (Ito et al.,1994, Plant Mol. Biol. 24: 863-878), a seed specific promoter such asthe glutelin, prolamin, globulin, or albumin promoter from rice (Wu etal., 1998, Plant and Cell Physiology 39: 885-889), a Vicia faba promoterfrom the legumin B4 and the unknown seed protein gene from Vicia faba(Conrad et al., 1998, Journal of Plant Physiology 152: 708-711), apromoter from a seed oil body protein (Chen et al., 1998, Plant and CellPhysiology 39: 935-941), the storage protein napA promoter from Brassicanapus, or any other seed specific promoter known in the art, e.g., asdescribed in WO 91/14772. Furthermore, the promoter may be a leafspecific promoter such as the rbcs promoter from rice or tomato (Kyozukaet al., 1993, Plant Physiology 102: 991-1000, the chlorella virusadenine methyltransferase gene promoter (Mitra and Higgins, 1994, PlantMolecular Biology 26: 85-93), or the aldP gene promoter from rice(Kagaya et al., 1995, Molecular and General Genetics 248: 668-674), or awound inducible promoter such as the potato pin2 promoter (Xu et al.,1993, Plant Molecular Biology 22: 573-588).

A promoter enhancer element may also be used to achieve higherexpression of the enzyme in the plant. For instance, the promoterenhancer element may be an intron which is placed between the promoterand the nucleotide sequence encoding a polypeptide of the presentinvention. For instance, Xu et al., 1993, supra disclose the use of thefirst intron of the rice actin 1 gene to enhance expression.

The selectable marker gene and any other parts of the expressionconstruct may be chosen from those available in the art.

The nucleic acid construct is incorporated into the plant genomeaccording to conventional techniques known in the art, includingAgrobacterium-mediated transformation, virus-mediated transformation,microinjection, particle bombardment, biolistic transformation, andelectroporation (Gasser et al., 1990, Science 244: 1293; Potrykus, 1990,Bio/Technology 8: 535; Shimamoto et al., 1989, Nature 338: 274).

Presently, Agrobacterium tumefaciens-mediated gene transfer is themethod of choice for generating transgenic dicots (for a review, seeHooykas and Schilperoort, 1992, Plant Molecular Biology 19: 15-38).However it can also be used for transforming monocots, although othertransformation methods are generally preferred for these plants.Presently, the method of choice for generating transgenic monocots isparticle bombardment (microscopic gold or tungsten particles coated withthe transforming DNA) of embryonic calli or developing embryos(Christou, 1992, Plant Journal 2: 275-281; Shimamoto, 1994, CurrentOpinion Biotechnology 5: 158-162; Vasil et al., 1992, Bio/Technology 10:667-674). An alternative method for transformation of monocots is basedon protoplast transformation as described by Omirulleh et al., 1993,Plant Molecular Biology 21: 415-428.

Following transformation, the transformants having incorporated thereinthe expression construct are selected and regenerated into whole plantsaccording to methods well-known in the art.

The present invention also relates to methods for producing apolypeptide of the present invention comprising (a) cultivating atransgenic plant or a plant cell comprising a nucleotide sequenceencoding a polypeptide having antimicrobial activity of the presentinvention under conditions conducive for production of the polypeptide;and (b) recovering the polypeptide.

Compositions

In a still further aspect, the present invention relates tocompositions, such as pharmaceutical compositions, comprising anantimicrobial polypeptide of the invention.

The composition may comprise a polypeptide of the invention as the majorpolypeptide component, e.g., a mono-component composition.Alternatively, the composition may comprise multiple enzymaticactivities, such as an aminopeptidase, amylase, carbohydrase,carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextringlycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase,beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase,haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase,pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase,polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase,or xylanase.

The compositions may further comprise another pharmaceutically activeagent, such as an additional biocidal agent, such as anotherantimicrobial polypeptide exhibiting antimicrobial activity as definedabove. The biocidal agent may be an antibiotic, as known in the art.Classes of antibiotics include penicillins, e.g., penicillin G,penicillin V, methicillin, oxacillin, carbenicillin, nafcillin,ampicillin, etc.; penicillins in combination with beta-lactamaseinhibitors, cephalosporins, e.g., cefaclor, cefazolin, cefuroxime,moxalactam, etc.; carbapenems; monobactams; aminoglycosides;tetracyclines; macrolides; lincomycins; polymyxins; sulfonamides;quinolones; cloramphenical; metronidazole; spectinomycin; trimethoprim;vancomycin; etc. The biocidal agent may also be an anti-mycotic agent,including polyenes, e.g., amphotericin B, nystatin; 5-flucosyn; andazoles, e.g., miconazol, ketoconazol, itraconazol and fluconazol.

In an embodiment the biocidal agent is a non-enzymatic chemical agent.In another embodiment the biocidal agent is a non-polypeptide chemicalagent.

The biocidal agent may be capable of reducing the number of living cellsof Escherichia coli (DSM 1576) to 1/100 after 8 hours (preferably after4 hours, more preferably after 2 hours, most preferably after 1 hour,and in particular after 30 minutes) incubation at 20° C. in an aqueoussolution of 25% (w/w); preferably in an aqueous solution of 10% (w/w);more preferably in an aqueous solution of 5% (w/w); even more preferablyin an aqueous solution of 1% (w/w); most preferably in an aqueoussolution of 0.5% (w/w); and in particular in an aqueous solution of 0.1%(w/w) of the biocidal agent.

The biocidal agent may also be capable of inhibiting the outgrowth ofEscherichia coli (DSM 1576) for 24 hours at 25° C. in a microbial growthsubstrate, when added in a concentration of 1000 ppm; preferably whenadded in a concentration of 500 ppm; more preferably when added in aconcentration of 250 ppm; even more preferably when added in aconcentration of 100 ppm; most preferably when added in a concentrationof 50 ppm; and in particular when added in a concentration of 25 ppm.

The biocidal agent may also be capable of reducing the number of livingcells of Bacillus subtilis (ATCC 6633) to 1/100 after 8 hours(preferably after 4 hours, more preferably after 2 hours, mostpreferably after 1 hour, and in particular after 30 minutes) incubationat 20° C. in an aqueous solution of 25% (w/w); preferably in an aqueoussolution of 10% (w/w); more preferably in an aqueous solution of 5%(w/w); even more preferably in an aqueous solution of 1% (w/w); mostpreferably in an aqueous solution of 0.5% (w/w); and in particular in anaqueous solution of 0.1% (w/w) of the biocidal agent.

The biocidal agent may also be capable of inhibiting the outgrowth ofBacillus subtilis (ATCC 6633) for 24 hours at 25° C. in a microbialgrowth substrate, when added in a concentration of 1000 ppm; preferablywhen added in a concentration of 500 ppm; more preferably when added ina concentration of 250 ppm; even more preferably when added in aconcentration of 100 ppm; most preferably when added in a concentrationof 50 ppm; and in particular when added in a concentration of 25 ppm.

The compositions may comprise a suitable carrier material. Thecompositions may also comprise a suitable delivery vehicle capable ofdelivering the antimicrobial polypeptides of the invention to thedesired locus when the compositions are used as a medicament.

The compositions may be prepared in accordance with methods known in theart and may be in the form of a liquid or a dry composition. Forinstance, the polypeptide composition may be in the form of a granulateor a microgranulate. The polypeptide to be included in the compositionmay be stabilized in accordance with methods known in the art.

Examples are given below of preferred uses of the polypeptidecompositions of the invention. The dosage of the polypeptide compositionof the invention and other conditions under which the composition isused may be determined on the basis of methods known in the art.

Methods and Uses

The present invention also encompasses various uses of the antimicrobialpolypeptides of the invention. The antimicrobial polypeptides aretypically useful at any locus subject to contamination by bacteria,fungi, yeast or algae. Typically, loci are in aqueous systems such ascooling water systems, laundry rinse water, oil systems such as cuttingoils, lubricants, oil fields and the like, where microorganisms need tobe killed or where their growth needs to be controlled. However, thepresent invention may also be used in all applications for which knownantimicrobial compositions are useful, such as protection of wood,latex, adhesive, glue, paper, cardboard, textile, leather, plastics,caulking, and feed.

Other uses include preservation of foods, beverages, cosmetics such aslotions, creams, gels, ointments, soaps, shampoos, conditioners,antiperspirants, deodorants, mouth wash, contact lens products, enzymeformulations, or food ingredients.

Thus, the antimicrobial polypeptides of the invention may by useful as adisinfectant, e.g., in the treatment of acne, infections in the eye orthe mouth, skin infections; in antiperspirants or deodorants; in footbath salts; for cleaning and disinfection of contact lenses, hardsurfaces, teeth (oral care), wounds, bruises and the like.

In general it is contemplated that the antimicrobial polypeptides of thepresent invention are useful for cleaning, disinfecting or inhibitingmicrobial growth on any hard surface. Examples of surfaces, which mayadvantageously be contacted with the antimicrobial polypeptides of theinvention are surfaces of process equipment used e.g., dairies, chemicalor pharmaceutical process plants, water sanitation systems, oilprocessing plants, paper pulp processing plants, water treatment plants,and cooling towers. The antimicrobial polypeptides of the inventionshould be used in an amount, which is effective for cleaning,disinfecting or inhibiting microbial growth on the surface in question.

Further, it is contemplated that the antimicrobial polypeptides of theinvention can advantageously be used in a cleaning-in-place (C.I.P.)system for cleaning of process equipment of any kind.

The antimicrobial polypeptides of the invention may additionally be usedfor cleaning surfaces and cooking utensils in food processing plants andin any area in which food is prepared or served such as hospitals,nursing homes, restaurants, especially fast food restaurants,delicatessens and the like. It may also be used as an antimicrobial infood products and would be especially useful as a surface antimicrobialin cheeses, fruits and vegetables and food on salad bars.

It may also be used as a preservation agent or a disinfection agent inwater based paints.

The antimicrobial polypeptides of the present invention are also usefulfor microbial control of water lines, and for disinfection of water, inparticular for disinfection of industrial water.

The invention also relates to the use of an antimicrobial polypeptide orcomposition of the invention as a medicament. Further, an antimicrobialpolypeptide or composition of the invention may also be used for themanufacture of a medicament for controlling or combating microorganisms,such as fungal organisms or bacteria, preferably gram positive bacteria.

The composition and antimicrobial polypeptide of the invention may beused as an antimicrobial veterinarian or human therapeutic orprophylactic agent. Thus, the composition and antimicrobial polypeptideof the invention may be used in the preparation of veterinarian or humantherapeutic agents or prophylactic agents for the treatment of microbialinfections, such as bacterial or fungal infections, preferably grampositive bacterial infections. In particular the microbial infectionsmay be associated with lung diseases including, but not limited to,tuberculosis, pneumonia and cystic fibrosis; and sexual transmitteddiseases including, but not limited to, gonorrhea and chlamydia.

The composition of the invention comprises an effective amount of theantimicrobial polypeptide of the invention.

The term “effective amount” when used herein is intended to mean anamount of the antimicrobial polypeptide comprising the amino acidsequence shown as amino acids 1 to 18 of anyone of SEQ ID NO: 2 to SEQID NO: 114, or a fragment or a variant thereof, which is sufficient toinhibit growth of the microorganisms in question.

The invention also relates to wound healing compositions or productssuch as bandages, medical devices such as, e.g., catheters and furtherto anti-dandruff hair products, such as shampoos.

Formulations of the antimicrobial polypeptides of the invention areadministered to a host suffering from or predisposed to a microbialinfection. Administration may be topical, localized or systemic,depending on the specific microorganism, preferably it will belocalized. Generally the dose of the antimicrobial polypeptides of theinvention will be sufficient to decrease the microbial population by atleast about 50%, usually by at least 1 log, and may be by 2 or more logsof killing. The compounds of the present invention are administered at adosage that reduces the microbial population while minimizing anyside-effects. It is contemplated that the composition will be obtainedand used under the guidance of a physician for in vivo use. Theantimicrobial polypeptides of the invention are particularly useful forkilling gram negative bacteria, including Pseudomonas aeruginosa, andChlamydia trachomatis; and gram-positive bacteria, includingstreptococci such as S. pneumonia, S. uberis, S. hyointestinalis, S.pyogenes or agalactiae; and staphylococci such as S. aureus, S.epidermidis, S. simulans, S, xylosus, S. carnosus.

Formulations of the antimicrobial polypeptides of the invention may beadministered to a host suffering from or predisposed to a microbial lunginfection, such as pneumonia; or to a microbial wound infection, such asa bacterial wound infection.

Formulations of the antimicrobial polypeptides of the invention may alsobe administered to a host suffering from or predisposed to a skininfection, such as acne, atopic dermatitis or seborrheic dermatitis;preferably the skin infection is a bacterial skin infection, e.g.,caused by Staphylococcus epidermidis, Staphylococcus aureus,Propionibacterium acnes, Pityrosporum ovale or Malassezia furfur.

The antimicrobial polypeptides of the invention are also useful for invitro formulations to kill microbes, particularly where one does notwish to introduce quantities of conventional antibiotics. For example,the antimicrobial polypeptides of the invention may be added to animaland/or human food preparations; or they may be included as an additivefor in vitro cultures of cells, to prevent the overgrowth of microbes intissue culture.

The susceptibility of a particular microbe to killing with theantimicrobial polypeptides of the invention may be determined by invitro testing, as detailed in the experimental section. Typically aculture of the microbe is combined with the antimicrobial polypeptide atvarying concentrations for a period of time sufficient to allow theprotein to act, usually between about one hour and one day. The viablemicrobes are then counted, and the level of killing determined.

Microbes of interest include, but are not limited to, Gram-negativebacteria, for example: Citrobacter sp.; Enterobacter sp.; Escherichiasp., e.g., E. coli; Klebsiella sp.; Morganella sp.; Proteus sp.;Providencia sp.; Salmonella sp., e.g., S. typhi, S. typhimurium;Serratia sp.; Shigella sp.; Pseudomonas sp., e.g., P. aeruginosa;Yersinia sp., e.g., Y. pestis, Y. pseudotuberculosis, Y. enterocolitica;Franciscella sp.; Pasturella sp.; Vibrio sp., e.g., V. cholerae, V.parahemolyticus; Campylobacter sp., e.g., C. jejuni; Haemophilus sp.,e.g., H. influenzae, H. ducreyi; Bordetella sp., e.g., B. pertussis, B.bronchiseptica, B. parapertussis; Brucella sp., Neisseria sp., e.g., N.gonorrhoeae, N. meningitidis, etc. Other bacteria of interest includeLegionella sp., e.g., L. pneumophila; Listeria sp., e.g., L.monocytogenes; Mycoplasma sp., e.g., M. hominis, M. pneumoniae;Mycobacterium sp., e.g., M. tuberculosis, M. leprae; Treponema sp.,e.g., T. pallidum; Borrelia sp., e.g., B. burgdorferi; Leptospirae sp.;Rickettsia sp., e.g., R. rickettsia, R. typhi; Chlamydia sp., e.g., C.trachomatis, C. pneumoniae, C. psittaci; Helicobacter sp., e.g., H.pylori, etc.

Non bacterial pathogens of interest include fungal and protozoanpathogens, e.g., Plasmodia sp., e.g., P. falciparum, Trypanosoma sp.,e.g., T. brucei; shistosomes; Entaemoeba sp., Cryptococcus sp., Candidasp., e.g., C. albicans; etc.

Various methods for administration may be employed. The polypeptideformulation may be given orally, or may be injected intravascularly,subcutaneously, peritoneally, by aerosol, opthalmically, intra-bladder,topically, etc. For example, methods of administration by inhalation arewell-known in the art. The dosage of the therapeutic formulation willvary widely, depending on the specific antimicrobial polypeptide to beadministered, the nature of the disease, the frequency ofadministration, the manner of administration, the clearance of the agentfrom the host, and the like. The initial dose may be larger, followed bysmaller maintenance doses. The dose may be administered as infrequentlyas weekly or biweekly, or fractionated into smaller doses andadministered once or several times daily, semi-weekly, etc. to maintainan effective dosage level. In many cases, oral administration willrequire a higher dose than if administered intravenously. The amidebonds, as well as the amino and carboxy termini, may be modified forgreater stability on oral administration. For example, the carboxyterminus may be amidated.

Formulations

The compounds of this invention can be incorporated into a variety offormulations for therapeutic administration. More particularly, thecompounds of the present invention can be formulated into pharmaceuticalcompositions by combination with appropriate, pharmaceuticallyacceptable carriers or diluents, and may be formulated into preparationsin solid, semi-solid, liquid or gaseous forms, such as tablets,capsules, powders, granules, ointments, creams, foams, solutions,suppositories, injections, inhalants, gels, microspheres, lotions, andaerosols. As such, administration of the compounds can be achieved invarious ways, including oral, buccal, rectal, parenteral,intraperitoneal, intradermal, transdermal, intracheal, etc.,administration. The antimicrobial polypeptides of the invention may besystemic after administration or may be localized by the use of animplant or other formulation that acts to retain the active dose at thesite of implantation.

In one embodiment, a formulation for topical use comprises a chelatingagent that decreases the effective concentration of divalent cations,particularly calcium and magnesium. For example, agents such as citrate,EGTA or EDTA may be included, where citrate is preferred. Theconcentration of citrate will usually be from about 1 to 10 mM.

The compounds of the present invention can be administered alone, incombination with each other, or they can be used in combination withother known compounds (e.g., perforin, anti-inflammatory agents,antibiotics, etc.) In pharmaceutical dosage forms, the compounds may beadministered in the form of their pharmaceutically acceptable salts. Thefollowing methods and excipients are merely exemplary and are in no waylimiting.

For oral preparations, the compounds can be used alone or in combinationwith appropriate additives to make tablets, powders, granules orcapsules, for example, with conventional additives, such as lactose,mannitol, corn starch or potato starch; with binders, such ascrystalline cellulose, cellulose derivatives, acacia, corn starch orgelatins; with disintegrators, such as corn starch, potato starch orsodium carboxymethylcellulose; with lubricants, such as talc ormagnesium stearate; and if desired, with diluents, buffering agents,moistening agents, preservatives and flavoring agents.

The compounds can be formulated into preparations for injections bydissolving, suspending or emulsifying them in an aqueous or nonaqueoussolvent, such as vegetable or other similar oils, synthetic aliphaticacid glycerides, esters of higher aliphatic acids or propylene glycol;and if desired, with conventional additives such as solubilizers,isotonic agents, suspending agents, emulsifying agents, stabilizers andpreservatives.

The compounds can be utilized in aerosol formulation to be administeredvia inhalation.

The compounds of the present invention can be formulated intopressurized acceptable propellants such as dichlorodifluoromethane,propane, nitrogen and the like.

The compounds can be used as lotions, for example to prevent infectionof burns, by formulation with conventional additives such assolubilizers, isotonic agents, suspending agents, emulsifying agents,stabilizers and preservatives.

Furthermore, the compounds can be made into suppositories by mixing witha variety of bases such as emulsifying bases or water-soluble bases. Thecompounds of the present invention can be administered rectally via asuppository. The suppository can include vehicles such as cocoa butter,carbowaxes and polyethylene glycols, which melt at body temperature, yetare solidified at room temperature.

Unit dosage forms for oral or rectal administration such as syrups,elixirs, and suspensions may be provided wherein each dosage unit, forexample, teaspoonful, tablespoonful, tablet or suppository, contains apredetermined amount of the composition containing one or more compoundsof the present invention. Similarly, unit dosage forms for injection orintravenous administration may comprise the compound of the presentinvention in a composition as a solution in sterile water, normal salineor another pharmaceutically acceptable carrier.

Implants for sustained release formulations are well-known in the art.Implants are formulated as microspheres, slabs, etc. with biodegradableor non-biodegradable polymers. For example, polymers of lactic acidand/or glycolic acid form an erodible polymer that is well-tolerated bythe host. The implant containing the antimicrobial polypeptides of theinvention is placed in proximity to the site of infection, so that thelocal concentration of active agent is increased relative to the rest ofthe body.

The term “unit dosage form”, as used herein, refers to physicallydiscrete units suitable as unitary dosages for human and animalsubjects, each unit containing a predetermined quantity of compounds ofthe present invention calculated in an amount sufficient to produce thedesired effect in association with a pharmaceutically acceptablediluent, carrier or vehicle. The specifications for the unit dosageforms of the present invention depend on the particular compoundemployed and the effect to be achieved, and the pharmacodynamicsassociated with the compound in the host.

The pharmaceutically acceptable excipients, such as vehicles, adjuvants,carriers or diluents, are readily available to the public. Moreover,pharmaceutically acceptable auxiliary substances, such as pH adjustingand buffering agents, tonicity adjusting agents, stabilizers, wettingagents and the like, are readily available to the public.

Typical dosages for systemic administration range from 0.1 pg to 100milligrams per kg weight of subject per administration. A typical dosagemay be one tablet taken from two to six times daily, or one time-releasecapsule or tablet taken once a day and containing a proportionallyhigher content of active ingredient. The time-release effect may beobtained by capsule materials that dissolve at different pH values, bycapsules that release slowly by osmotic pressure, or by any other knownmeans of controlled release.

Those of skill will readily appreciate that dose levels can vary as afunction of the specific compound, the severity of the symptoms and thesusceptibility of the subject to side effects. Some of the specificcompounds are more potent than others. Preferred dosages for a givencompound are readily determinable by those of skill in the art by avariety of means. A preferred means is to measure the physiologicalpotency of a given compound.

The use of liposomes as a delivery vehicle is one method of interest.The liposomes fuse with the cells of the target site and deliver thecontents of the lumen intracellularly. The liposomes are maintained incontact with the cells for sufficient time for fusion, using variousmeans to maintain contact, such as isolation, binding agents, and thelike. In one aspect of the invention, liposomes are designed to beaerosolized for pulmonary administration. Liposomes may be prepared withpurified proteins or peptides that mediate fusion of membranes, such asSendai virus or influenza virus, etc. The lipids may be any usefulcombination of known liposome forming lipids, including cationic orzwitterionic lipids, such as phosphatidylcholine. The remaining lipidwill normally be neutral or acidic lipids, such as cholesterol,phosphatidyl serine, phosphatidyl glycerol, and the like.

For preparing the liposomes, the procedure described by Kato et al.,1991, J. Biol. Chem. 266: 3361 may be used. Briefly, the lipids andlumen composition containing peptides are combined in an appropriateaqueous medium, conveniently a saline medium where the total solids willbe in the range of about 1-10 weight percent. After intense agitationfor short periods of time, from about 5-60 sec., the tube is placed in awarm water bath, from about 25-40° C. and this cycle repeated from about5-10 times. The composition is then sonicated for a convenient period oftime, generally from about 1-10 sec. and may be further agitated byvortexing. The volume is then expanded by adding aqueous medium,generally increasing the volume by about from 1-2 fold, followed byshaking and cooling. This method allows for the incorporation into thelumen of high molecular weight molecules.

Formulations with Other Active Agents

For use in the subject methods, the antimicrobial polypeptides of theinvention may be formulated with other pharmaceutically active agents,particularly other antimicrobial agents. Other agents of interestinclude a wide variety of antibiotics, as known in the art. Classes ofantibiotics include penicillins, e.g., penicillin G, penicillin V,methicillin, oxacillin, carbenicillin, nafcillin, ampicillin, etc.;penicillins in combination with beta-lactamase inhibitors,cephalosporins, e.g., cefaclor, cefazolin, cefuroxime, moxalactam, etc.;carbapenems; monobactams; aminoglycosides; tetracyclines; macrolides;lincomycins; polymyxins; sulfonamides; quinolones; cloramphenical;metronidazole; spectinomycin; trimethoprim; vancomycin; etc.

Anti-mycotic agents are also useful, including polyenes, e.g.,amphotericin B, nystatin; 5-flucosyn; and azoles, e.g., miconazol,ketoconazol, itraconazol and fluconazol. Antituberculotic drugs includeisoniazid, ethambutol, streptomycin and rifampin. Cytokines may also beincluded in a formulation of the antimicrobial polypeptides of theinvention, e.g., interferon gamma, tumor necrosis factor alpha,interleukin 12, etc.

In Vitro Synthesis

The antimicrobial peptides of the invention may be prepared by in vitrosynthesis, using conventional methods as known in the art. Variouscommercial synthetic apparatuses are available, for example automatedsynthesizers by Applied Biosystems Inc., Beckman, etc. By usingsynthesizers, naturally occurring amino acids may be substituted withunnatural amino acids, particularly D-isomers (or D-forms) e.g.,D-alanine and D-isoleucine, diastereoisomers, side chains havingdifferent lengths or functionalities, and the like. The particularsequence and the manner of preparation will be determined byconvenience, economics, purity required, and the like.

Chemical linking may be provided to various peptides or proteinscomprising convenient functionalities for bonding, such as amino groupsfor amide or substituted amine formation, e.g., reductive amination,thiol groups for thioether or disulfide formation, carboxyl groups foramide formation, and the like.

If desired, various groups may be introduced into the peptide duringsynthesis or during expression, which allow for linking to othermolecules or to a surface. Thus cysteines can be used to makethioethers, histidines for linking to a metal ion complex, carboxylgroups for forming amides or esters, amino groups for forming amides,and the like.

The polypeptides may also be isolated and purified in accordance withconventional methods of recombinant synthesis. A lysate may be preparedof the expression host and the lysate purified using HPLC, exclusionchromatography, gel electrophoresis, affinity chromatography, or otherpurification technique. For the most part, the compositions which areused will comprise at least 20% by weight of the desired product, moreusually at least about 75% by weight, preferably at least about 95% byweight, and for therapeutic purposes, usually at least about 99.5% byweight, in relation to contaminants related to the method of preparationof the product and its purification. Usually, the percentages will bebased upon total protein

Animal Feed

The present invention is also directed to methods for using thepolypeptides having antimicrobial activity in animal feed, as well as tofeed compositions and feed additives comprising the antimicrobialpolypeptides of the invention.

The term animal includes all animals, including human beings. Examplesof animals are non-ruminants, and ruminants, such as cows, sheep andhorses. In a particular embodiment, the animal is a non-ruminant animal.Non-ruminant animals include mono-gastric animals, e.g., pigs or swine(including, but not limited to, piglets, growing pigs, and sows);poultry such as turkeys and chicken (including but not limited tobroiler chicks, layers); young calves; and fish (including but notlimited to salmon).

The term feed or feed composition means any compound, preparation,mixture, or composition suitable for, or intended for intake by ananimal.

In the use according to the invention the antimicrobial polypeptide canbe fed to the animal before, after, or simultaneously with the diet. Thelatter is preferred.

In a particular embodiment, the antimicrobial polypeptide, in the formin which it is added to the feed, or when being included in a feedadditive, is well defined. Well-defined means that the antimicrobialpolypeptide preparation is at least 50% pure as determined bySize-exclusion chromatography (see Example 12 of WO 01/58275). In otherparticular embodiments the antimicrobial polypeptide preparation is atleast 60, 70, 80, 85, 88, 90, 92, 94, or at least 95% pure as determinedby this method.

A well-defined antimicrobial polypeptide preparation is advantageous.For instance, it is much easier to dose correctly to the feed anantimicrobial polypeptide that is essentially free from interfering orcontaminating other antimicrobial polypeptides. The term dose correctlyrefers in particular to the objective of obtaining consistent andconstant results, and the capability of optimizing dosage based upon thedesired effect.

For the use in animal feed, however, the antimicrobial polypeptide neednot be that pure; it may e.g., include other enzymes, in which case itcould be termed an antimicrobial polypeptide preparation.

The antimicrobial polypeptide preparation can be (a) added directly tothe feed (or used directly in a treatment process of vegetableproteins), or (b) it can be used in the production of one or moreintermediate compositions such as feed additives or premixes that issubsequently added to the feed (or used in a treatment process). Thedegree of purity described above refers to the purity of the originalantimicrobial polypeptide preparation, whether used according to (a) or(b) above.

Antimicrobial polypeptide preparations with purities of this order ofmagnitude are in particular obtainable using recombinant methods ofproduction, whereas they are not so easily obtained and also subject toa much higher batch-to-batch variation when the antimicrobialpolypeptide is produced by traditional fermentation methods.

Such antimicrobial polypeptide preparation may of course be mixed withother enzymes.

The term vegetable proteins as used herein refers to any compound,composition, preparation or mixture that includes at least one proteinderived from or originating from a vegetable, including modifiedproteins and protein-derivatives. In particular embodiments, the proteincontent of the vegetable proteins is at least 10, 20, 30, 40, 50, or 60%(w/w).

Vegetable proteins may be derived from vegetable protein sources, suchas legumes and cereals, for example materials from plants of thefamilies Fabaceae (Leguminosae), Cruciferaceae, Chenopodiaceae, andPoaceae, such as soy bean meal, lupin meal and rapeseed meal.

In a particular embodiment, the vegetable protein source is materialfrom one or more plants of the family Fabaceae, e.g., soybean, lupine,pea, or bean.

In another particular embodiment, the vegetable protein source ismaterial from one or more plants of the family Chenopodiaceae, e.g.,beet, sugar beet, spinach or quinoa.

Other examples of vegetable protein sources are rapeseed, and cabbage.

Soybean is a preferred vegetable protein source.

Other examples of vegetable protein sources are cereals such as barley,wheat, rye, oat, maize (corn), rice, and sorghum.

The antimicrobial polypeptide can be added to the feed in any form, beit as a relatively pure antimicrobial polypeptide, or in admixture withother components intended for addition to animal feed, i.e., in the formof animal feed additives, such as the so-called pre-mixes for animalfeed.

In a further aspect the present invention relates to compositions foruse in animal feed, such as animal feed, and animal feed additives,e.g., premixes.

Apart from the antimicrobial polypeptide of the invention, the animalfeed additives of the invention contain at least one fat solublevitamin, and/or at least one water soluble vitamin, and/or at least onetrace mineral, and/or at least one macro mineral.

Further, optional, feed-additive ingredients are coloring agents, aromacompounds, stabilizers, and/or at least one other enzyme selected fromamongst phytases EC 3.1.3.8 or 3.1.3.26; xylanases EC 3.2.1.8;galactanases EC 3.2.1.89; and/or beta-glucanases EC 3.2.1.4.

In a particular embodiment these other enzymes are well defined (asdefined above for antimicrobial polypeptide preparations).

Examples of other antimicrobial peptides (AMP's) are CAP18, Leucocin A,Tritrpticin, Protegrin-1, Thanatin, Defensin, Ovispirin such asNovispirin (Robert Lehrer, 2000), and variants, or fragments thereofwhich retain antimicrobial activity.

Examples of other antifungal polypeptides (AFP's) are the Aspergillusgiganteus, and Aspergillus niger peptides, as well as variants andfragments thereof which retain antifungal activity, as disclosed in WO94/01459 and WO 02/090384.

Usually fat and water soluble vitamins, as well as trace minerals formpart of a so-called premix intended for addition to the feed, whereasmacro minerals are usually separately added to the feed. Either of thesecomposition types, when enriched with an antimicrobial polypeptide ofthe invention, is an animal feed additive of the invention.

In a particular embodiment, the animal feed additive of the invention isintended for being included (or prescribed as having to be included) inanimal diets or feed at levels of 0.01 to 10.0%; more particularly 0.05to 5.0%; or 0.2 to 1.0% (% meaning g additive per 100 g feed). This isso in particular for premixes.

The following are non-exclusive lists of examples of these components:

Examples of fat soluble vitamins are vitamin A, vitamin D3, vitamin E,and vitamin K, e.g., vitamin K3.

Examples of water soluble vitamins are vitamin B12, biotin and choline,vitamin B1, vitamin B2, vitamin B6, niacin, folic acid andpanthothenate, e.g., Ca-D-panthothenate.

Examples of trace minerals are manganese, zinc, iron, copper, iodine,selenium, and cobalt.

Examples of macro minerals are calcium, phosphorus and sodium.

The nutritional requirements of these components (exemplified withpoultry and piglets/pigs) are listed in Table A of WO 01/58275.Nutritional requirement means that these components should be providedin the diet in the concentrations indicated.

In the alternative, the animal feed additive of the invention comprisesat least one of the individual components specified in Table A of WO01/58275. At least one means either of, one or more of, one, or two, orthree, or four and so forth up to all thirteen, or up to all fifteenindividual components. More specifically, this at least one individualcomponent is included in the additive of the invention in such an amountas to provide an in-feed-concentration within the range indicated incolumn four, or column five, or column six of Table A.

The present invention also relates to animal feed compositions. Animalfeed compositions or diets have a relatively high content of protein.Poultry and pig diets can be characterised as indicated in Table B of WO01/58275, columns 2-3. Fish diets can be characterised as indicated incolumn 4 of this Table B. Furthermore such fish diets usually have acrude fat content of 200-310 g/kg.

An animal feed composition according to the invention has a crudeprotein content of 50-800 g/kg, and furthermore comprises at least oneantimicrobial polypeptide as claimed herein.

Furthermore, or in the alternative (to the crude protein contentindicated above), the animal feed composition of the invention has acontent of metabolizable energy of 10-30 MJ/kg; and/or a content ofcalcium of 0.1-200 g/kg; and/or a content of available phosphorus of0.1-200 g/kg; and/or a content of methionine of 0.1-100 g/kg; and/or acontent of methionine plus cysteine of 0.1-150 g/kg; and/or a content oflysine of 0.5-50 g/kg.

In particular embodiments, the content of metabolizable energy, crudeprotein, calcium, phosphorus, methionine, methionine plus cysteine,and/or lysine is within any one of ranges 2, 3, 4 or 5 in Table B of WO01/58275 (R. 2-5).

Crude protein is calculated as nitrogen (N) multiplied by a factor 6.25,i.e., Crude protein (g/kg)=N (g/kg)×6.25. The nitrogen content isdetermined by the Kjeldahl method (A.O.A.C., 1984, Official Methods ofAnalysis 14th ed., Association of Official Analytical Chemists,Washington D.C.).

Metabolisable energy can be calculated on the basis of the NRCpublication Nutrient requirements in swine, ninth revised edition 1988,subcommittee on swine nutrition, committee on animal nutrition, board ofagriculture, national research council. National Academy Press,Washington, D.C., pp. 2-6, and the European Table of Energy Values forPoultry Feed-stuffs, Spelderholt centre for poultry research andextension, 7361 DA Beekbergen, The Netherlands. Grafisch bedrijf Ponsen& looijen by, Wageningen. ISBN 90-71463-12-5.

The dietary content of calcium, available phosphorus and amino acids incomplete animal diets is calculated on the basis of feed tables such asVeevoedertabel 1997, gegevens over chemische samenstelling,verteerbaarheid en voederwaarde van voedermiddelen, CentralVeevoederbureau, Runderweg 6, 8219 pk Lelystad. ISBN 90-72839-13-7.

In a particular embodiment, the animal feed composition of the inventioncontains at least one vegetable protein or protein source as definedabove.

In still further particular embodiments, the animal feed composition ofthe invention contains 0-80% maize; and/or 0-80% sorghum; and/or 0-70%wheat; and/or 0-70% Barley; and/or 0-30% oats; and/or 0-40% soybeanmeal; and/or 0-10% fish meal; and/or 0-20% whey. Animal diets can e.g.,be manufactured as mash feed (non pelleted) or pelleted feed. Typically,the milled feed-stuffs are mixed and sufficient amounts of essentialvitamins and minerals are added according to the specifications for thespecies in question. Enzymes can be added as solid or liquid enzymeformulations. For example, a solid enzyme formulation is typically addedbefore or during the mixing step; and a liquid enzyme preparation istypically added after the pelleting step. The enzyme may also beincorporated in a feed additive or premix.

The final enzyme concentration in the diet is within the range of0.01-200 mg enzyme protein per kg diet, for example in the range of 5-30mg enzyme protein per kg animal diet.

The antimicrobial polypeptide may be administered in one or more of thefollowing amounts (dosage ranges): 0.01-200; or 0.01-100; or 0.05-100;or 0.05-50; or 0.10-10—all these ranges being in mg antimicrobialpolypeptide protein per kg feed (ppm).

For determining mg antimicrobial polypeptide protein per kg feed, theantimicrobial polypeptide is purified from the feed composition, and thespecific activity of the purified antimicrobial polypeptide isdetermined using a relevant assay (see under antimicrobial activity,substrates, and assays). The antimicrobial activity of the feedcomposition as such is also determined using the same assay, and on thebasis of these two determinations, the dosage in mg antimicrobialpolypeptide protein per kg feed is calculated.

The same principles apply for determining mg antimicrobial polypeptideprotein in feed additives. Of course, if a sample is available of theantimicrobial polypeptide used for preparing the feed additive or thefeed, the specific activity is determined from this sample (no need topurify the antimicrobial polypeptide from the feed composition or theadditive).

Detergent Compositions

The antimicrobial polypeptides of the invention may be added to and thusbecome a component of a detergent composition.

The detergent composition of the invention may for example be formulatedas a hand or machine laundry detergent composition including a laundryadditive composition suitable for pre-treatment of stained fabrics and arinse added fabric softener composition, or be formulated as a detergentcomposition for use in general household hard surface cleaningoperations, or be formulated for hand or machine dishwashing operations.

In a specific aspect, the invention provides a detergent additivecomprising the antimicrobial polypeptides of the invention and asurfactant. The detergent additive as well as the detergent compositionmay comprise one or more other enzymes such as a protease, a lipase, acutinase, an amylase, a carbohydrase, a cellulase, a pectinase, amannanase, an arabinase, a galactanase, a xylanase, an oxidase (such asa laccase), and/or a peroxidase (such as a haloperoxidase).

In general the properties of the chosen enzyme(s) should be compatiblewith the selected detergent, (i.e., pH-optimum, compatibility with otherenzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) shouldbe present in effective amounts.

Proteases: Suitable proteases include those of animal, vegetable ormicrobial origin. Microbial origin is preferred. Chemically modified orprotein engineered mutants are included. The protease may be a serineprotease or a metallo protease, preferably an alkaline microbialprotease or a trypsin-like protease. Examples of alkaline proteases aresubtilisins, especially those derived from Bacillus, e.g., subtilisinNovo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 andsubtilisin 168 (described in WO 89/06279). Examples of trypsin-likeproteases are trypsin (e.g., of porcine or bovine origin) and theFusarium protease described in WO 89/06270 and WO 94/25583.

Examples of useful proteases are the variants described in WO 92/19729,WO 98/20115, WO 98/20116, and WO 98/34946, especially the variants withsubstitutions in one or more of the following positions: 27, 36, 57, 76,87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235 and274.

Lipases: Suitable lipases include those of bacterial or fungal origin.Chemically modified or protein engineered mutants are included. Examplesof useful lipases include lipases from Humicola (synonym Thermomyces),e.g., from H. lanuginosa (T. lanuginosus) as described in EP 258 068 andEP 305 216 or from H. insolens as described in WO 96/13580, aPseudomonas lipase, e.g., from P. alcaligenes or P. pseudoalcaligenes(EP 218 272), P. cepacia (EP 331 376), P. stutzeri (GB 1,372,034), P.fluorescens, Pseudomonas sp. strain SD 705 (WO 95/06720 and WO96/27002), P. wisconsinensis (WO 96/12012), a Bacillus lipase, e.g.,from B. subtilis (Dartois et al., 1993, Biochemica et Biophysica Acta,1131: 253-360), B. stearothermophilus (JP 64/744992) or B. pumilus (WO91/16422).

Other examples are lipase variants such as those described in WO92/05249, WO 94/01541, EP 407 225, EP 260 105, WO 95/35381, WO 96/00292,WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079 and WO97/07202.

Amylases: Suitable amylases (alpha and/or beta) include those ofbacterial or fungal origin. Chemically modified or protein engineeredmutants are included. Amylases include, for example, alpha-amylasesobtained from Bacillus, e.g., a special strain of B. licheniformis,described in more detail in GB 1,296,839.

Examples of useful amylases are the variants described in WO 94/02597,WO 94/18314, WO 96/23873, and WO 97/43424, especially the variants withsubstitutions in one or more of the following positions: 15, 23, 105,106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243,264, 304, 305, 391, 408, and 444.

Cellulases: Suitable cellulases include those of bacterial or fungalorigin. Chemically modified or protein engineered mutants are included.Suitable cellulases include cellulases from the genera Bacillus,Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, e.g., the fungalcellulases produced from Humicola insolens, Myceliophthora thermophilaand Fusarium oxysporum disclosed in U.S. Pat. No. 4,435,307, U.S. Pat.No. 5,648,263, U.S. Pat. No. 5,691,178, U.S. Pat. No. 5,776,757 and WO89/09259.

Especially suitable cellulases are the alkaline or neutral cellulaseshaving color care benefits. Examples of such cellulases are cellulasesdescribed in EP 0 495 257, EP 0 531 372, WO 96/11262, WO 96/29397, WO98/08940. Other examples are cellulase variants such as those describedin WO 94/07998, EP 0 531 315, U.S. Pat. No. 5,457,046, U.S. Pat. No.5,686,593, U.S. Pat. No. 5,763,254, WO 95/24471, WO 98/12307 andPCT/DK98/00299.

Peroxidases/Oxidases: Suitable peroxidases/oxidases include those ofplant, bacterial or fungal origin. Chemically modified or proteinengineered mutants are included. Examples of useful peroxidases includeperoxidases from Coprinus, e.g., from C. cinereus, and variants thereofas those described in WO 93/24618, WO 95/10602, and WO 98/15257.

The detergent enzyme(s) may be included in a detergent composition byadding separate additives containing one or more enzymes, or by adding acombined additive comprising all of these enzymes. A detergent additiveof the invention, i.e., a separate additive or a combined additive, canbe formulated e.g., as a granulate, a liquid, a slurry, etc. Preferreddetergent additive formulations are granulates, in particularnon-dusting granulates, liquids, in particular stabilized liquids, orslurries.

Non-dusting granulates may be produced, e.g., as disclosed in U.S. Pat.Nos. 4,106,991 and 4,661,452 and may optionally be coated by methodsknown in the art. Examples of waxy coating materials are poly(ethyleneoxide) products (polyethyleneglycol, PEG) with mean molar weights of1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethyleneoxide units; ethoxylated fatty alcohols in which the alcohol containsfrom 12 to 20 carbon atoms and in which there are 15 to 80 ethyleneoxide units; fatty alcohols; fatty acids; and mono- and di- andtriglycerides of fatty acids. Examples of film-forming coating materialssuitable for application by fluid bed techniques are given in GB1483591. Liquid enzyme preparations may, for instance, be stabilized byadding a polyol such as propylene glycol, a sugar or sugar alcohol,lactic acid or boric acid according to established methods. Protectedenzymes may be prepared according to the method disclosed in EP 238,216.

The detergent composition of the invention may be in any convenientform, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid. Aliquid detergent may be aqueous, typically containing up to 70% waterand 0-30% organic solvent, or non-aqueous.

The detergent composition comprises one or more surfactants, which maybe non-ionic including semi-polar and/or anionic and/or cationic and/orzwitterionic. The surfactants are typically present at a level of from0.1% to 60% by weight.

When included therein the detergent will usually contain from about 1%to about 40% of an anionic surfactant such as linearalkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fattyalcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate,alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid orsoap.

When included therein the detergent will usually contain from about 0.2%to about 40% of a non-ionic surfactant such as alcohol ethoxylate,nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamineoxide,ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide,polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives ofglucosamine (“glucamides”).

The detergent may contain 0-65% of a detergent builder or complexingagent such as zeolite, diphosphate, triphosphate, phosphonate,carbonate, citrate, nitrilotriacetic acid, ethylenediaminetetraaceticacid, diethylenetriaminepentaacetic acid, alkyl- or alkenylsuccinicacid, soluble silicates or layered silicates (e.g., SKS-6 from Hoechst).

The detergent may comprise one or more polymers. Examples arecarboxymethylcellulose, poly(vinylpyrrolidone), poly (ethylene glycol),poly(vinyl alcohol), poly(vinylpyridine-N-oxide), poly(vinylimidazole),polycarboxylates such as polyacrylates, maleic/acrylic acid copolymersand lauryl methacrylate/acrylic acid copolymers.

The detergent may contain a bleaching system which may comprise a H₂O₂source such as perborate or percarbonate which may be combined with aperacid-forming bleach activator such as tetraacetylethylenediamine ornonanoyloxybenzenesulfonate. Alternatively, the bleaching system maycomprise peroxyacids of e.g., the amide, imide, or sulfone type.

The enzyme(s) of the detergent composition of the invention may bestabilized using conventional stabilizing agents, e.g., a polyol such aspropylene glycol or glycerol, a sugar or sugar alcohol, lactic acid,boric acid, or a boric acid derivative, e.g., an aromatic borate ester,or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid,and the composition may be formulated as described in e.g., WO 92/19709and WO 92/19708.

The detergent may also contain other conventional detergent ingredientssuch as e.g., fabric conditioners including clays, foam boosters, sudssuppressors, anti-corrosion agents, soil-suspending agents, anti-soilredeposition agents, dyes, bactericides, optical brighteners,hydrotropes, tarnish inhibitors, or perfumes.

It is at present contemplated that in the detergent compositions anyenzyme, and the antimicrobial polypeptides of the invention, may beadded in an amount corresponding to 0.01-100 mg of enzyme protein perliter of wash liquor, preferably 0.05-10 mg of enzyme protein per literof wash liquor, more preferably 0.1-5 mg of enzyme protein per liter ofwash liquor, and most preferably 0.1-1 mg of enzyme protein per liter ofwash liquor.

The antimicrobial polypeptides of the invention may additionally beincorporated in the detergent formulations disclosed in WO 97/07202which is hereby incorporated as reference.

The present invention is further described by the following exampleswhich should not be construed as limiting the scope of the invention.

EXAMPLES

Chemicals used as buffers and substrates were commercial products of atleast reagent grade.

Example 1

Evaluation of Antimicrobial Activity

A range of antimicrobial polypeptides, which are variants of SEQ ID NO:1, were expressed in E. coli TOP10 (Invitrogen) using arabinose asinducer, as disclosed in Example 1 of International patent applicationWO 00/73433 (with minor modifications). Expression of the antimicrobialpolypeptides of the invention resulted in growth inhibition of the hostcells.

Briefly, fresh overnight cultures grown in RM medium containing 0.2%glucose and ampicillin (100 μg/ml) were diluted 300-fold into 150microliter of RM medium containing 0.2% glycerol and ampicillin (100μg/ml) and 0.01% arabinose in a microtiter plate and incubated at 37degrees Celsius with vigorous shaking. The growth curve was monitored bymeasuring OD450 using a Bioscreen C Microbiology reader (Thermo ElectronCorporation) at intervals of 30 minutes for 14 hours (see Invitrogenprotocol of the pBAD/gIII A, B and C vectors catalogue nos. V450-01 forbuffer and media composition).

The percentage of growth inhibition was calculated as the end point ODmeasurement of each sample divided by the end point OD measurementobtained from cells containing the control vector and multiplied by 100.The formula is the following:(1−(sample OD−blank OD)/(control vector OD−blank OD))×100where “blank OD” corresponds to the OD of an empty well.

The amino acid substitutions compared to SEQ ID NO: 1, and theantimicrobial effects of the corresponding polypeptides are listed inTable 1. The wildtype was included as a standard in each experiment.TABLE 1 Amino acid substitutions Growth inhibition using 0.01% comparedto arabinose SEQ ID NO: 1 SEQ ID NO: (%) wildtype 1 75 L3I 25 81 N2S +R4C 105 90 R4C 37 91 R4C + I13V 106 90 R4C + K16I 107 87 R4H + K15R 10888 I6V + K9I + I14L 102 94 I7L 45 75 K9I + H12Q 103 93 K9I + K16R + G18D104 93 K9I 55 96 G10W 63 77 I11F 67 84 I11R 65 77 H12L 74 79 I13F 76 81K15S 86 77 Y17L 91 82 Y17F 90 84 Y17K 89 80 G18L 95 81 G18V 100 86 G18R96 83 wildtype 1 69 N2I + R8C 109 96 R4C + K9R 110 89 wildtype 1 55R8C + I14T 111 62 K9N 57 58 Y17F 90 74 wildtype 1 40 R4C + I6F 112 74R4H + R8C 113 73 G10V 64 64 wildtype 1 79 N2M 19 92 N2S 17 90 N2A 12 92N2F 14 91 N2T 13 93 N2I 7 92 N2Y 10 89 N2V 16 90 N2H 20 87 N2L 18 90 N2C21 94 L3I 25 92 R4F 28 95 R4I 34 96 R4L 30 92 R4Y 36 98 R4V 32 96 R4A 3394 R4T 35 86 N2K + I7L + Y17S 114 93 I7W 46 83 R8L 47 84 wildtype 1 74I6L 40 92 I6W 41 93 I6M 42 84 K9Y 51 97 K9I 55 99 K9C 54 97 G10C 61 94G10L 60 89 G10F 59 84 G10W 63 89 H12S 70 92 H12I 68 91 H12N 73 90wildtype 1 82 K9V 52 92 K9F 53 97 I11W 66 96 H12C 71 93 H12A 72 90 I13L77 91 I13F 76 93 I14L 80 94 I14F 79 93 K15I 83 98 K15S 86 82 K15L 84 98Y17L 91 88 wildtype 1 86 K15R 85 90 K16R 87 91 G18L 95 86 G18R 96 91G18F 93 94 G18L 95 91 G18I 94 90 G18T 98 86 wildtype 1 69 Y17F 90 81Y17K 89 85 G18C 99 86

The results shown in Table 1 indicate convincingly that all the testedantimicrobial polypeptides exhibit strong antimicrobial activity.

Example 2

Polypeptides with Antimicrobial Activity Designed by QSAR

50 clones containing random mutations in the wildtype gene originated byError Prone PCR were picked randomly from the E. coli TOP10 library.These clones were analyzed in the Bioscreen OD reader to quantify thedegree of growth inhibition of the different clones compared to wildtype in the presence of arabinose (see Example 1 for details). Allclones were sequenced to determine the nature of the mutation(s). Theresulting data was used for the QSAR model.

Based on the QSAR model, several variants were predicted to haveimproved antimicrobial activity compared to the wildtype. 15 of thesevariants were cloned into the pBAD vector and tested for improvedactivity in the Suicide Expression System (see Example 1).

Oligonucleotides encoding the wildtype and containing the differentmutations K9V, N2F, N2I, N2I+K9L, N2W, R4I, G18I, H12K, H12R, K9F, K9L,N2L, N2A, N2M, K9Y were annealed and filled-in using Klenow (Boheringer,DNA pol I, Large Fragment) following the protocol described in SambrookJ., Fritsch E. F and Maniatis T (Molecular Cloning, A Laboratory Manual,second edition. Cold spring Harbor Laboratory Press, 1989).

The double strand oligonucleotides where then digested with NcoI/XbaIand directional inserted into pBAD gIII A. All constructs were sequencedto confirm the mutations. These constructs were then transformed into E.coli TOP10 cells and the resulting transformants were assayed in theBioscreen OD reader to quantify the degree of growth inhibition by usingthe Suicide Expression System (see Example 1).

To establish a Quantitative Structure Activity Relationship (QSAR)model, structures of the variants isolated with the Suicide ExpressionSystem, were modeled in silico. Physicochemical parameters based onpartial surface area of peptides and molecular interactions field (MIF)were computed and related to the biological activity. From this QSARmodel, a predictive activity of all possible single residue mutants wasproposed. 15 variants containing the different mutations, K9V, N2F, N2I,N2I+K9L, N2W, R4I, G18I, H12K, H12R, K9F, K9L, N2L, N2A, N2M, K9Y weretested and validated using the Suicide Expression System (SES).

The growth inhibition obtained with the wildtype and the differentvariants using the Suicide Expression System are shown in the tablebelow: Amino acid substitutions Growth inhibition using 0.01% comparedto arabinose SEQ ID NO: 1 SEQ ID NO. (%) wildtype 1 77 N2L 18 82 N2A 1281 N2M 19 81 N2F 14 82 N2W 15 84 N2I 7 81 N2I + K9L 8 94 R4I 34 91 K9V52 90 K9F 53 94 K9L 50 88 K9Y 51 90 H12K 69 89 H12R — 87 G18I 94 82

Example 3

Cloning, Expression and Evaluation of Antimicrobial Polypeptides

Cloning of Synthetic Gene Encoding the Wildtype

In order to produce the wildtype (SEQ ID NO: 1) for antimicrobialactivity assays, a synthetic gene was made (see below) and inserted intothe expression vector pET31 b+ (Novagen Inc.). The synthetic gene wasconstituted by specifically designed oligonucleotides (Primer1 andPrimer2). Synthetic gene encoding the wildtype: (SEQ ID NO: 115) AAA AACCTG CGT CGC ATT ATC CGC AAA GGC ATC CAT ATC ATT AAA AAA TAT GGC TAGK   N   L   R   R   I   I   R   K   C   I   H   I   I   K   K   Y   C   *Primer 1: (SEQ ID NO: 117) ATTATTCAGA TGCTGGATCC GGACGAAAAA AACCTGCGTCGCATTATCCG CAAAGGCATC CATATCATTA AAAAATATGG CTAATAACTC GAGATTATT Primer2: (SEQ ID NO: 118) AATAATCTCG AGTTATTAGC CATATTTTTT AATGATATGGATGCCTTTGC GGATAATGCG ACGCAGGTTT TTTTCGTCCG GATCCAGCAT CTGAATAAT

Enzymatic digestion of flanking restriction endonuclease sites(AlwNI/AvaI) enabled us to clone this synthetic gene as a fusionconstruct in pET31b+ (standard procedures as described by themanufacturer, New England Biolabs Inc.). All standard protocols havebeen described elsewhere (Sambrook, Fritsch, and Maniatis, 1989).

Transformation in E. coli

Recombinant pET31b+ was transformed into E. coli Novablue as describedby the manufacturer (Novagen). Plasmid was prepared by QIAprep MiniColumns (QIAGEN Inc.) and sequenced by automated sequencing usingplasmid specific primers (Primer3 and Primer4): Primer 3: (SEQ ID NO:119) TGCTA GTTAT TGCTC AGCGG Primer 4: (SEQ ID NO: 120) ACCGT AGTTGCGCCC ATCGCloning the Variants

A method of direct plasmid amplification was used to generate plasmidthat encode single mutants of the wildtype at a specified position inthe sequence for further validation of suggested variants from SES, QSARand rational design (see above examples).

As an example, to generate plasmid encoding a variant with an arginineto valine mutation in the fourth position of the wildtype, we designedPrimer 5 and Primer 6. By direct amplification of the plasmid bypolymerase chain reaction, treatment with DpnI and transformation in E.coli Novablue we were able to recover variants with the defined mutationin position 4. Primer 5: 5′-G GAA AAA AAC CTG

CGG ATT ATC CG-3′ 5′-G GAA AAA AAC CTG CGT CGC ATT ATC CG-3′ 3′-C CTTTTT TTG GAC GCA GCG TAA TAG GC-5′ Primer 6: 3′-C CTT TTT TTG GAC

GCG TAA TAG GC-5′ Variant encoded: K N L R/V R I IExpression in E. coli

Plasmid was transformed in E. coli BLR-DE3 according to the manufacturer(Novagen). Bacteria were cultivated in LB media to OD₆₀₀˜0.8 andrecombinant protein synthesis was initiated by 1 mM IPTG (Isopropylbeta-D-Thiogalactopyranoside). Upon 3 hours of induction, bacteria wereharvested, re-suspended in 1/10 volume buffer A (50 mM Tris-HCl, 1 mMEDTA, 100 mM NaCl, pH 8) and lysed by pressure disruption (1500 mBar).Resulting pellet was washed twice in buffer B (50 mM Tris-HCl, 10 mMEDTA, 0.5% TritonX-100, 100 mM NaCl, pH 8). All standard protocols havebeen described elsewhere (Sambrook, Fritsch, and Maniatis, 1989).

Purification of Antimicrobial Peptides from E. coli Inclusion Bodies

The pellet resulting from the above purification contained purifiedinclusion bodies. To liberate the peptide from the KSI fusion partner,acid hydrolysis was performed on an engineered Asp-Pro site, introducedN-terminally to the gene encoding the wildtype. Inclusion bodies werere-suspended in 100 mM sodium phosphate (pH 2.3) and incubated overnightat 85 degrees Celsius. Resulting supernatant contained peptide(Pro-Arg-Glu-wildtype). The sample was neutralized by adding 100 mMsodium phosphate (pH 12.3). In order to maturate the peptide, thepeptide was treated with a glutamyl endopeptidase I (from B.licheniformis). The maturated peptide was confirmed by mass-spectrometryand further purified by standard chromatographic procedures.

Example 4

Generation of Antimicrobial Polypeptide Variants

The above example was also used to generate random mutations at position2 and 4, using degenerate primers, replacing a specific codon by arandom codon (NNN). This is depicted by Primer 7+8 below, making randomvariants in position 4. Random variants in position 2 was also generatedusing Primer 9+10 Primer 7: 5′-G GAA AAA AAC CTG

CGG ATT ATC CG-3′ 5′-G GAA AAA AAC CTG CGT CGC ATT ATC CG-3′ 3′-C CTTTTT TTG GAC GCA GCG TAA TAG GC-5′ Primer 8: 3′-C CTT TTT TTG GAC

GCG TAA TAG GC-5′ Variant encoded: K N L ? R I I AA Position # 1 2 3 4 56 7 Primer 9: 5′-GCG GAA AAA

CTG CGT CGG ATT ATC C-3′ 5′-GCG GAA AAA AAC CTG CGT CGC ATT ATC C-3′3′-CGC CTT TTT TTG GAC GCA GCG TAA TAG G-5′ Primer 10: 3′-CGC CTT TTT

GAC GCA GCG TAA TAG G-5′ Variant encoded: K ? L R R I I AA Position # 12 3 4 5 6 7

Mutations of individual clones were verified by DNA sequencing. Thevariants were expressed and purified as described in Example 3.

Direct antimicrobial activity of purified variants was evaluated asdescribed below (Example 5). The following 4 variants were found to bebetter than wildtype against Staphylococcus aureus (MICs are presentedin microgram/ml). S. aureus Variant SEQ ID NO. Position (ATCC 29737)wildtype  1 — ≧128 N2R — 2 12 R4G 27 4 64 R4Q 29 4 64 R4P 31 4 64

Example 5

Antimicrobial Activity of Selected Antimicrobial Polypeptides byMicrobroth Dilution Assay (MIC)

The direct antimicrobial activity through measures of Minimal InhibitoryConcentrations (MIC) of the antimicrobial polypeptides was evaluatedusing the Microbroth Dilution Assay. Variants were produced as shown inthe above examples or through chemical synthesis. The protocol usedfollows the recommendation by NCCLS (www.nccls.org), usingcation-adjusted Mueller hinton broth. Bacteria isolates fromStaphylococcus aureus (ATCC 29737) and Staphylococcus epidermidis (DSM1798) were used to characterize the activity of the peptides. MICs arepresented in microgram/ml.

The table below shows the results: S. aureus S. epidermidis Variant SEQID NO. (ATCC 29737) (DSM 1798) wildtype 1 ≧128 48 N2W 15 4 1 N2I + K9L 84 3 N2F + G18F 101 4 2 L3W + H12R 24 6 2 N2G + K9W 6 6 2 G10F 59 6 2 R4L30 8 16 K9F 53 8 3 G18F 93 8 3 N2R — 12 16 K9L 50 12 6 K15I 83 12 6 K15L84 12 8 N2L 18 16 8 K9V 52 16 8 G18L 95 16 6 N2V 16 24 16 R4F 28 24 16K9Y 51 24 8 G18I 94 24 8 N2I 7 32 12 N2Y 10 32 12 N2D 11 32 32 N2F 14 326 L3W 23 32 8 R4I 34 32 24 I6L 40 32 24 I11W 66 32 12 H12I 68 32 16 G18R96 32 6 N2R + I11R 9 48 24 I14L 80 48 8 R4V 32 64 32 H12K 69 64 8 H12R —64 8 I13F 76 64 8 I13L 77 64 12 K15R 85 64 16 Y17L 91 64 16 I14F 79 9616 N2T 13 32 48 N2S 17 128 24 L3I 25 128 24 H12S 70 128 16 Y17F 90 12824

1-23. (canceled)
 24. A polypeptide having antimicrobial activity,comprising the amino acid sequence set forth in SEQ ID NO: 2:K-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17; whereinX1=N, F, I, W, M, S, A, T, Y, V, H, L, C, K or G; X2=L, I, F or W; X3=R,I, F, L, Y, V, A, T, C, H, G, Q or P; X4=R or C; X5=I, L, W, M, V or F;X6=I, L or W; X7=R, L, T or C; X8=K, V, F, L, C, Y, I, R, N or W; X9=G,C, Y, L, F, W or V; X10=, W, F or R; X11=H, K, C, A, S, I, N, L or Q;X12=I, L, F or V; X13=I, L, F, T or V; X14=K, I, S, L or R; X15=K, R orI; X16=Y, I, L, F or K; X17=G, I, S, L, R, F, T, C or V; and wherein theamino acid sequence has more than 55% identity and less than 100%identity with amino acids 1 to 18 of SEQ ID NO:
 1. 25. A polypeptidehaving antimicrobial activity, comprising the amino acid sequence setforth in SEQ ID NO: 3:K-R-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16; wherein X3=Ror C; X4=I, L, W, M, V or F; X5=I, L or W; X6=R, L, T or C; X7=K, V, F,L, C, Y, I, R, N or W; X8=G, C, Y, L, F, W or V; X9=I, W, F or R; X10=H,K, C, A, S, I, N, L or Q; X11=I, L, F or V; X12=I, L, F, T or V; X13=K,I, S, L or R; X14=K, R or I; X15=Y, I, L, F or K; X16=G, I, S, L, R, F,T, C or V; and wherein the amino acid sequence has more than 55%identity and less than 90% identity with amino acids 1 to 18 of SEQ IDNO:
 1. 26. A polypeptide having antimicrobial activity, comprising theamino acid sequence set forth in SEQ ID NO: 4:K-X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-R-X11-X12-X13-X14-X15-X16; whereinX1=N, F, I, W, M, S, A, T, Y, V, H, L, C, K or G; X2=L, I, F or W; X3=R,I, F, L, Y, V, A, T, C, H, G, Q or P; X4=R or C; X5=I, L, W, M, V or F;X6=I, L or W; X7=R, L, T or C; X8=K, V, F, L, C, Y, I, R, N or W; X9=G,C, Y, L, F, W or V; X10=I, W, F or R; X11=I, L, F or V; X12=I, L, F, Tor V; X13=K, I, S, L or R; X14=K, R or I; X15=Y, I, L, F or K; X16=G, I,S, L, R, F, T, C or V; and wherein the amino acid sequence has more than55% identity and less than 90% identity with amino acids 1 to 18 of SEQID NO:
 1. 27. The polypeptide of claim 24, wherein the amino acidsequence has at least 60% identity with amino acids 1 to 18 of SEQ IDNO:
 1. 28. The polypeptide of claim 24, which comprises the amino acidsequence of anyone of SEQ ID NO: 5 to SEQ ID NO:
 114. 29. Thepolypeptide of claim 24, which consists of the amino acid sequence ofanyone of SEQ ID NO: 5 to SEQ ID NO:
 114. 30. A composition comprising apolypeptide of claim
 24. 31. The composition of claim 30, which furthercomprises an additional biocidal agent.
 32. A detergent compositioncomprising a surfactant and a polypeptide of claim
 24. 33. An animalfeed additive comprising (a) at least one polypeptide of claim 24; and(b) at least one fat soluble vitamin, and/or (c) at least one watersoluble vitamin, and/or (d) at least one trace mineral, and/or (e) atleast one macro mineral.
 34. The animal feed additive of claim 33, whichfurther comprises phytase, xylanase, galactanase, and/or beta-glucanase.35. An animal feed composition having a crude protein content of 50 to800 g/kg and comprising at least one polypeptide of claim
 24. 36. Amethod for killing or inhibiting growth of microbial cells comprisingcontacting the microbial cells with a polypeptide of claim
 24. 37. Apolynucleotide having a nucleotide sequence which encodes for thepolypeptide of claim
 24. 38. A nucleic acid construct comprising thenucleotide sequence of claim 37 operably linked to one or more controlsequences that direct the production of the polypeptide in a suitablehost.
 39. A recombinant expression vector comprising the nucleic acidconstruct of claim
 38. 40. A recombinant host cell comprising thenucleic acid construct of claim
 38. 41. A method for producing apolypeptide, comprising: (a) cultivating a recombinant host cell asdefined in claim 40 under conditions conducive for production of thepolypeptide; and (b) recovering the polypeptide.
 42. A transgenic plant,plant part or plant cell, which has been transformed with a nucleotidesequence encoding a polypeptide of claim 24.